

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 01:27:44 +0000  
**To:** Barton Haynes, M.D.  
**Subject:** RE:

Thanks, Bart.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Barton Haynes, M.D. <(b) (6)>  
Sent: Saturday, February 29, 2020 8:25 PM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
Subject: RE:

Great job in the press conference today.

Tough and high pressure situations it seems.

Thanks for being there and representing truth and science... best b

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
Sent: Saturday, February 29, 2020 7:14 PM  
To: Barton Haynes, M.D. (b) (6); Marovich, Mary (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] <(b) (6)>  
Subject: RE:

Impressive!

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It

should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Barton Haynes, M.D. <[REDACTED] (b) (6)>

Sent: Saturday, February 29, 2020 2:29 PM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Marovich, Mary (NIH/NIAID) [E] [REDACTED] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] [REDACTED] (b) (6)

Subject: FW:

Hi Tony, Mary and Carl:

Every Saturday am, the DHVI team meets in my office to work on moving the HIV vaccine work forward, and now a new contingent is also working on coronavirus vaccine and new therapeutics.

This picture was from 9 am this Saturday morning. Great and dedicated crew listening to the presentation of data!

Best bart

-----Original Message-----

From: Barton Haynes, M.D.

Sent: Saturday, February 29, 2020 2:25 PM

To: [REDACTED] (b) (6)

Subject:

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 01:09:29 +0000  
**To:** Routh, Jennifer (NIH/NIAID) [E]  
**Subject:** RE: Clips

Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>  
Sent: Saturday, February 29, 2020 10:32 AM  
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
Cc: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>  
Subject: RE: Clips

Dr. Fauci - the clips I've been able to pull so far are listed below:

Hardball (MSNBC last night): [https://www.msnbc.com/hardball/watch/dr-anthony-fauci-i-m-not-being-muzzled-79650373756?cid=sm\\_npd\\_ms\\_tw\\_hb](https://www.msnbc.com/hardball/watch/dr-anthony-fauci-i-m-not-being-muzzled-79650373756?cid=sm_npd_ms_tw_hb)

Lou Dobbs (Fox Business last night): <https://twitter.com/LouDobbs/status/1233555383190507520>

Today (NBC this morning): <https://www.today.com/video/dr-fauci-on-coronavirus-fears-no-need-to-change-lifestyle-yet-79684677616>

Thanks,  
Jen

Jennifer Routh [E]  
News and Science Writing Branch  
Office of Communications and Government Relations National Institute of Allergy and Infectious Diseases (NIAID)  
NIH/HHS  
31 Center Drive Room 7A17C  
Bethesda, MD 20892  
Direct: (b) (6)  
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive

information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
Sent: Saturday, February 29, 2020 8:42 AM  
To: Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6) >  
Subject: Clips

Jen:

This AM I did NBC Today and MSNBC. Please make sure that I get the clips.

Thanks

Tony



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 01:05:03 +0000  
**To:** Holland, Steven (NIH/NIAID) [E]  
**Subject:** RE: Human lung mice

Lease the decision up to HHS.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Holland, Steven (NIH/NIAID) [E] (b) (6)  
**Sent:** Saturday, February 29, 2020 11:03 AM  
**To:** (b) (6) Fauci, Anthony (NIH/NIAID) [E]  
(b) (6)  
**Subject:** Re: Human lung mice

Thanks for the note, (b) (5)

Steve

--

Director, Division of Intramural Research  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Bldg. 10/11N248 MSC 1960  
Bethesda, MD 20892-1960  
(b) (6) voice  
301-480-4507 fax  
(b) (6) email

Assistant lab: (b) (6)  
(b) (6)

Assistant to SD: (b) (6)  
(b) (6)

---

**From:** (b) (6)  
**Date:** Saturday, February 29, 2020 at 10:55 AM  
**To:** Anthony Fauci (b) (6), Steven Holland (b) (6)  
**Subject:** Human lung mice

Hi Tony and Steve, I thought I'd better fill you in on some recent communications. Dr.

(b) (5)

[Redacted content]

(b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 00:55:28 +0000  
**To:** (b) (6)  
**Subject:** RE: in case you need to hear it

Michael:

Thanks for the note. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Michael Specter (b) (6)  
**Sent:** Saturday, February 29, 2020 12:39 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** in case you need to hear it

You are one of my very few heroes.

And in case you have not seen it, here is my personal love letter to the president (in which you feature semi prominently)

<https://www.newyorker.com/news/daily-comment/donald-trumps-anti-globalist-response-to-a-global-coronavirus>

Michael Specter  
Staff Writer  
The New Yorker  
Adjunct Professor of Bioengineering  
Stanford University

(b) (6)  
Phone: (Work, Cell, SMS) (b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 00:53:55 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: COVID-19

Please take a look and respond. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Fred Schaich <fred.schaich@ifaratv.org>  
Sent: Saturday, February 29, 2020 12:55 PM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
Subject: COVID-19

Dear Dr. Fauci,

I'll not be at the CROI this year (b) (6)  
So I hope I may be able to ask  
you a few questions as a concerned citizen.

Will we learn:

Why there are new cases in the US of unknown origin?

Could this virus infect carriers who do not present with symptoms or present in various levels of very mild infection and never get identified as infected?

Could individuals host the virus differently due to genetics or ethnicity?

Is this virus consistently similar after multiple generation or is it capable of mutating?

Is there an ability to develop an antibody immunity through infection? Can one be reinfected?

Could the level of infection be determined by the amount of inoculant?

Could we learn the level of infect ability of this virus by testing everyone in a given geographic area where there is a deep outbreak? We might also learn about the pathogenesis in a way that we cannot learn otherwise.

If this virus is so transmissible could we end up with almost everyone eventually being infected and present with various levels of serious acute infection and death to indistinguishable cases or just carriers?

With the clamp/filter on information from this administration, please tell us where we may find regular reports at various levels of current science on what we learn about this virus and vaccine progress, and where we may ask questions? I hope there is place for formal and informal community input into treatment, care and vaccine development.

Thank you for all your help over the years with your wise perspective through our interviews and leadership at the



NIH in such a reasonable and responsible way

Warm regards,

Fred

Fred Schaich

(b) (6) OR

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 00:27:04 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Coronavirus - New Idea for treatment & clinical study  
**Attachments:** The Nine Lives of Hydroxychloroquine.docx, Chloroquine & COVID-19 pneumonia.pdf, Remdesivir & Chloroquine Effective InVitro Against COVID-19.pdf, 6-27-19 (5).jpg

Please take a look and respond to them. Thanks.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** (b) (6) >  
**Sent:** Saturday, February 29, 2020 7:23 PM  
**To:** vice.president@whitehouse.gov  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Redfield, Robert R. (CDC/OD)  
(b) (6) Secretary@HHS.gov  
**Subject:** Coronavirus - New Idea for treatment & clinical study  
**Importance:** High

Dear Vice President Pence,

We are thankful for your leadership of the White House Coronavirus Task Force in gathering the latest information about the outbreak, working with doctors and scientists to find solutions, and communicating with the general public regarding the situation. We were blessed to meet with you back in August, 2019, when (b) (6) had expressed a desire to meet you. I have attached a picture from our meeting to help you remember. We pray for you often.

Since we are both physicians, we have been following the details of the COVID-19 outbreak closely. My husband was researching the anti-viral drug remdesivir this morning, and he came across some articles from Chinese studies that indicated a very well-known drug called hydroxychloroquine (already widely used for 70 years to treat malaria and rheumatological diseases) had very potent activity against COVID-19 infection and pneumonia. This was rather surprising to us, but as we read about the study and the characteristics of hydroxychloroquine, we realized that this could be a very good drug to use for the treatment of high-risk patients infected with COVID-19, who might deteriorate rapidly and progress to hospitalization and need for ICU care. Remdesivir also seems like an excellent anti-viral drug, but it is given intravenously, and is probably reserved for COVID-19 patients who are already entering into severe respiratory distress in the hospital.

**Hydroxychloroquine, on the other hand, is given orally, and is cheap and readily available.**

Low doses (6.5 mg / kg) have been effective in the management of Systemic Lupus Erythematosus and Rheumatoid Arthritis. 200 mg tablets are usually prescribed twice a day with meals; dosage can be increased up to the recommended 6.5 mg/kg if the patient tolerates the lower dose. **We wondered if the low dose hydroxychloroquine would be able to be studied quickly in various COVID-19 patients, especially those who are older and / or with medical conditions that put them at higher risk for pneumonia and complications (cardiovascular disease, chronic pulmonary disease, hypertension, diabetes, etc.). In addition, hydroxychloroquine may even be a useful drug to prevent the development of pneumonia in patients diagnosed with COVID-19.**

**Because hydroxychloroquine is an older drug that is generic, current pharmaceutical companies have no incentive to do studies or research on its effectiveness for any new medical conditions. Therefore, the federal government would most likely have to construct and fund the studies. Perhaps Dr. Fauci has already considered this kind of study with hydroxychloroquine.**

We understand that vaccines are already being studied, and Israel is working on an oral (pill) vaccine. Vaccines take time to go through testing and trials, which is why we are suggesting to you that studies be done on hydroxychloroquine, a readily-available oral drug that could “bridge the gap” to provide some potential

treatment and mitigation of the COVID-19 infections while vaccines are being developed and mass produced.

We have attached several articles, which are electronic publications made available in advance (Feb. 4<sup>th</sup> & Feb 19<sup>th</sup>, 2020) of the printed journal publications. We will send a copy of this email to Dr. Fauci, Dr. Redfield, and Dr. Azar.

Sincerely yours,  
Drs. Paul & Karyl Stanton

(b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 00:14:14 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Please handle. Thanks.

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** (b) (6)  
**Sent:** Saturday, February 29, 2020 2:10 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** One solution in the armoury to protect Health Care Sector Workers against Covid-19

Dear Dr Fauci

A PPE device, tested and proven at **Public Health England Porton Down** (PHE), based on innovative technology could be ready to go into production within 20 weeks. It sterilises all airborne pathogens as air is inhaled by the wearer. See [www.medi-immune.com](http://www.medi-immune.com) and in particular the published report on the tests, by clicking on the report under "The Science" The device is due to undergo further tests, at PHE within the next week, specifically against Covid-19. For verification please contact Professor Nigel Silman at PHE Porton Down.

Health Services around the world are doing what they can to prepare for a significant increase in infections from this highly transmissible virus and if those people in the Health Care Sectors are infected the situation could become untenable.

The production of vaccines is under way but no one expects them to be available within the next 12 to 18 months. The Medi-Immune "ProtectivAir®", which has been under development for some years and could be available within a few months, will give a far greater level of protection than the current masks and respirators and more importantly can remain in use in the future for other emerging airborne pathogens – known, unknown or mutating.

Please take a little time to investigate this option, via the website, or pass it on to those who you believe need to be made aware of it. I will be happy to answer any questions, technical or otherwise, at my email address below or on my mobile number, also below.

Kind regards

James Love

James Love  
**Director**

m: [REDACTED] (b) (6)

t: [REDACTED]

[www.medi-immune.com](http://www.medi-immune.com)

[www.revaxbiotech.com](http://www.revaxbiotech.com)

## MEDI-IMMUNE

Groundbreaking Protection & Immunity

Medi-Immune Limited, registered in England and Wales | Company registration No: 04554706 | Registered Office: 4 Lady Bank | Tamworth Staffordshire | B79 7NB | UK

DISCLAIMER: Privileged/Confidential information and/or Copyright Material may be contained in this email. The information and material is intended for the use of the addressee(s) only. If you are not the addressee or the person responsible for delivering it to the intended addressee(s), you may not copy or deliver it to anyone else or use it in any unauthorised manner. To do so is prohibited and may be unlawful. If you receive this email by mistake, advise the sender immediately by using the reply facility in your email software. Any views or opinions presented are solely those of the author and do not necessarily represent those of Medi-Immune Ltd. Although this email and attachments are believed to be free of any virus or other defects which might affect any computer or IT systems into which they are received, no responsibility is accepted by Medi-Immune Ltd for any loss of damage arising in any way from the receipt or use thereof.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 00:12:45 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: A sharing on COVID ARDS research  
**Attachments:** Dexamethasone for COVID-19 for Dr. Tugwell.doc, Tsai 2020\_Ann of Intensive Care ARDS\_corticosteroid.pdf

Please take a look at this and handle. Thanks.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Paul Elias Alexander (b) (6) >  
**Sent:** Saturday, February 29, 2020 2:34 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** A sharing on COVID ARDS research

Hi Dr. Fauci, I am a trained epidemiologist and expert in evidence based medicine. Particularly in developing clinical practice guidelines and I teach EBM and GRADE methods.

You have no idea how much I have admired you across the years, your intelligence and poise.

May I ask how I may help you in this matter, this response, I am not talking about money, I wish to help, volunteer.

I draw your attention to 2 attachments...

1) one is a one page I wrote to summarize a meta analysis my team just completed and seeking to publish. It pertains to corticosteroids and ARDS. We are raising that this suggests indirect evidence that we may be able to extrapolate to the COVID patient with severe illness. This within the life threatening issue and emergency and no effective treatment. I share if this can

help you as I know you are leading this and listened to you today with the president. I support this president fully.

2) I share a paper published today, it on the other hand raises serious questions on the use of corticosteroids in influenza associated ARDS, and one may argue this patient set, is the closest to the COVID 19 patient.

My sense is that the accumulated evidence thus far is weak and argues against corticosteroids. For example, this recently published multicenter retrospective cohort study in medical center ICUs across Taiwan sought to assess the effectiveness of corticosteroids in patients presenting with influenza-associated ARDS (virology-proven ARDS and are on mechanical ventilation). Researchers examined the impact of early corticosteroid treatment ( $\geq 200$  mg hydrocortisone equivalent dose within 3 days after ICU admission, determined by a sensitivity analysis) on subsequent hospital mortality. The study revealed that of the 241 patients with influenza-associated ARDS, those receiving early corticosteroid had a significantly higher hospital mortality rate than those who did not get early corticosteroid [43.5% (37/85) vs. 19.2% (30/156),  $p < 0.001$ ]. Early corticosteroid treatment was independently associated with increased hospital mortality in overall patients [an adjusted OR of 5.02 (95% CI 2.39-10.54),  $p < 0.001$ ] and in all examined subgroups. Researchers found that a higher dose and earlier treatment was linked to higher hospital mortality. Moreover, they found that earlier treatment was related to a significantly increased odds of subsequent bacteremia [an adjusted OR of 2.37 (95% CI 1.01-5.56)]. These results underscore the urgency for robust comparative randomized research given this study is based on weaker observational evidence that is confounded by selection bias and confounded. However this was a stronger study that used statistical adjustment and propensity score matching. Thus this study suggests caution with corticosteroid and thus the importance for caution by clinicians as to the potential harms of corticosteroids in this population. These results, while based on weaker methodology, have revealed large estimates of effect, is the strongest evidence to date on treatment for ARDS, and brings us closest to the COVID-19 ARDS patient.

Best,

Paul E. Alexander, MSc, MHSc, PhD  
Assistant Professor  
<http://hei.mcmaster.ca/>  
McMaster University, 1280 Main Street W,  
Hamilton, ON L8S 4K1  
GUIDE Research Methods Group  
<http://guidecanada.org/>



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:56:39 +0000  
**To:** Les Gardonyi  
**Subject:** RE: Suggestion

Leslie:

Thank you for your note. We are actually looking into the effect of ACE inhibitors on the coronavirus.

Best regards,

Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Les Gardonyi (b) (6) >  
**Sent:** Saturday, February 29, 2020 3:06 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Suggestion

Dear Mr. Fauci,

This may be way too presumptive of a note...

As an engineer I've always liked to understand the mechanics of how things work so I looked into educating myself about the coronavirus and it's mechanics. (b) (6)

(b) (6) I've correlated a possible research route for your organization regarding the prevention aspect.

A quick overlook on this strategy is the following:

Coronaviruses are RNA viruses that typically enter human cells when their glycoproteins bind proteins on the cell surface. In the case of the virus that causes SARS, that human protein is **angiotensin-converting enzyme 2 (ACE2)**. At this time, scientists think the novel coronavirus is similar enough to SARS that its entry point is likely ACE2 as well.

source: <https://cen.acs.org/biological-chemistry/infectious-disease/novel-coronavirus-hits-China/98/web/2020/01>

[Irbesartan](#) is used to treat [high blood pressure \(hypertension\)](#) and to help protect the [kidneys](#) from damage due to [diabetes](#). Lowering [high blood pressure](#) helps prevent strokes, [heart attacks](#), and [kidney](#) problems. Irbesartan belongs to a class of drugs called **angiotensin receptor blockers** (ARBs). It works by relaxing [blood](#) vessels so that blood can flow more easily.

source: <https://www.webmd.com/drugs/2/drug-4720/irbesartan-oral/details>

Idea:

Can Irbesartan, being an angiotensin receptor blocker, possibly help prevent Coronavirus infections... since the Coronavirus entry to humans is via ACE-2?

I share this suggestion with you in the hopes that it may help your department in the research to prevent the spread of the coronavirus... or to a presumptuous email slated for deletion.

Sincerely,

-Leslie Gardonyi

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:54:27 +0000  
**To:** Ellen Butler  
**Subject:** RE: [REDACTED] (b) (6)

Ellen:

Thank you for your kind note. Very nice family pictures! [REDACTED] (b) (6)

[REDACTED], but in any event, thanks for the note.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: [REDACTED] (b) (6)  
FAX: (301) 496-4409  
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Ellen Butler [REDACTED] (b) (6)  
**Sent:** Saturday, February 29, 2020 3:13 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** [REDACTED] (b) (6)

I just watched you this afternoon at the press conference. Over the years I have seen you and wondered along with family members if [REDACTED] (b) (6)

Also I just wanted to say how professional you are and that I don't believe what #45 or his administration have to say regarding the coronavirus but have 100% confidence in what you say and do. Thank you for being the adult in the room.

[REDACTED] (b) (6) I am very proud of you.

Sincerely,

Ellen Butler



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:44:17 +0000  
**To:** Margaret Liu  
**Subject:** RE: kudos and comment about JAMA Coronavirus article

Margaret:

Thanks for the note. You make a valid point and I appreciate what you are saying. . On that issue, I have been vocal about making sure that we do not stigmatize Chinese people here in the USA or anywhere in relationship to the COVID-19 outbreak.

Best regards,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Margaret Liu <liu@protherimmune.com>  
**Sent:** Saturday, February 29, 2020 3:55 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>  
**Cc:** Alice Huang <stephen.lin@80-20ef.org>; president@80-20.us  
**Subject:** kudos and comment about JAMA Coronavirus article

Dear Tony,

Wonderful articles in JAMA and NEJM. So glad you are still heading NIAID- it is comforting that there are experts of your caliber still in the room. And thrilled that the NIAID has done so much to develop rapid timelines for DNA vaccines and that you highlighted that progress in the article, since people call me the "Mother of DNA vaccines,".

As a former NIAID Council member, I felt I should write to raise an issue that I am sensitized to as a scientist who is ethnically Chinese while American:

Why in the JAMA article was it necessary to state that the first travel-related case to the US was a *Chinese* man (italics mine) who had visited Wuhan. Did his being Chinese either ethnically or by citizenship affect anything biologically?



I ask because not only have many Asian people now encountered increased racism in public places (due to fear that any Asian person is a source of COVID-19), but now that the President is turning this epidemic into additional fear-mongering about "borders" it seems all the more important that scientists do not inadvertently add to "xenophobia" (even though non-white skin does not mean a person is foreign) and do not seem to advance any political perspective.

Sincerely and with best personal regards,  
Margaret

Margaret A. Liu, MD, DSchc, MDhc, FISV  
**ProTherImmune** &  
Foreign Adjunct Professor, Karolinska Institute  
Stockholm, Sweden  
Adjunct Full Professor, UCSF  
San Francisco, CA USA  
President Emeritus, International Society for Vaccines  
[Liu@ProTherImmune.com](mailto:Liu@ProTherImmune.com)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:40:04 +0000  
**To:** Tom Leopold  
**Cc:** Casseti, Cristina (NIH/NIAID) [E]  
**Subject:** RE: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

I have received this message and we are in fact looking into this.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

**From:** Tom Leopold (b) (6)>  
**Sent:** Saturday, February 29, 2020 4:24 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:34:59 +0000  
**To:** Tom Leopold  
**Subject:** RE: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Thanks for the note. We are looking into this possibility.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Tom Leopold (b) (6)>  
Sent: Saturday, February 29, 2020 5:01 PM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
Subject: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:29:47 +0000  
**To:** Richard Goodman  
**Subject:** RE: Coronavirus question

Richard:

There are no CDC-issued travel restrictions within the USA. The CDC made this clear at the White House press conference this afternoon.

Best regards,

Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Richard Goodman <goodmanr@ohsu.edu>  
**Sent:** Saturday, February 29, 2020 5:31 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Coronavirus question

We met many years ago, Tony,

...at an event marking Shelly Wolff's 10 year anniversary at New England Medical Center. (I had the distinction of being the first medical intern in that program who he reamed out.)

My question relates to travel restrictions. The current restrictions appear to be quite limited, but several organizations, including Google, Amazon, and the HHMI have restricted, or cancelled, even domestic meetings. As a result of the HHMI cancelation, my own program director indicated his intention to cancel our upcoming Scientific Advisory meeting and, in the non-academic world, (b) (6)

(which is ironic since there are more coronavirus infections in my town of (b) (6) Oregon than there are in all of New York).

In addition to announcing the new travel restrictions, could you also say something publicly about what doesn't need to be restricted? In particular, is domestic travel OK, or not? Does the HHMI know something the rest of us don't?

Sincerely,

Richard Goodman MD PhD

Vollum Institute  
Oregon Health & Science University

Sent from my iPad



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:06:38 +0000  
**To:** Casetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Rapid Collaboration for Hand & Nasal Decontamination Formulation  
**Attachments:** NORS-viral review\_V3.pdf, 1998 Reiss NO plays a role in viral infections.pdf, 2005 Akerstrom NO inhibits Corona Viral replication.pdf, 2010 Jung Nitric & SARS corona virus.pdf, 2013 Regev Nitric reduces viral infectivity.pdf, 2015Regev Nitric cattle vs antibiotics BRD.pdf

Please handle. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Gilly Regev (b) (6)  
**Sent:** Saturday, February 29, 2020 5:50 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Chris Miller (b) (6)  
**Subject:** Fwd: Rapid Collaboration for Hand & Nasal Decontamination Formulation

Dear Dr Fauci,

Dr Murad sits on our BOD and has suggested that we contact you to help expedite a rapid testing of our product on the COVID-19 virus. I know you are probably overwhelmed but hope you might pass this along or suggest a strategy that would be a win-win for us all.

We have developed a non-alcohol based formulation that utilizes the nanomolecule nitric oxide (NO). as you know, NO is produced in our body and is our first line of defense against microbes. We have harnessed this in a patented formulation called nitric oxide releasing solution/gel (NORGS). We are focused on the development of products for chronic sinusitis, diabetic foot wounds, warts and toenail fungus.

However, internally & personally, we have been using NORGS as an extremely effective natural hand sanitizer and nasal spray to protect ourselves from the common cold and flu for years.

There are strong independent published research that NO is antiviral against Corona viral species. We hae data showing definite virucidal characteristics and moderate antiviral effects in host cells.

With the recent concern with COVID-19, we felt we should try to rapidly test the hand rub and nasal spray against the COVID-19 but need to collaborate with a laboratory that could test this for us. Funding collaborators are welcome too, as this was not in our budget but we feel a social responsibility to move this forward.

I have included a short white paper of our data and a few articles to support our claims.

Feel free to contact me any time (b) (6) or have one of your senior staff contact me.

Sincerely,

Chris Miller and Gilly Regev

--

**Gilly Regev, Ph.D.**

CEO / Co-founder

SaNOtize Research and Development Corp.

Phone: (b) (6)

email: (b) (6)

<https://www.linkedin.com/in/gilly-regev-694b4a16/>

<https://www.sanotize.com>

**From:** (b) (6)  
**Sent:** Sat, 29 Feb 2020 06:58:29 -0500  
**To:** Heather DaVia  
**Subject:** Re: Thank You

Joseph and Heather:

Many thanks for your kind words. Much appreciated.  
Best regards,  
Tony

> On Feb 28, 2020, at 8:45 PM, Heather DaVia (b) (6) > wrote:

>

> Dear Dr. Fauci:

>

> Please accept my personal and heartfelt thanks for your continued efforts to keep the American public informed concerning the coronavirus. While listening to you on the radio or at press conferences, your calm, thoughtful, and measured words are very comforting and reassuring. Both your caring response and scientific/medical expertise are an example of the very best in the Federal Government.

>

> Again, thank you for your public service and your efforts to keep us as safe as possible.

>

> Sincerely,

>

> Joseph P. DaVia

> (b) (6)

>

> P.S. (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 03:15:14 +0000  
**To:** Tabak, Lawrence (NIH/OD) [E]  
**Cc:** Collins, Francis (NIH/OD) [E]; Schwetz, Tara (NIH/OD) [E]  
**Subject:** RE: OSTP call

Larry:

Thanks you very much.


Tony

---

**From:** Tabak, Lawrence (NIH/OD) [E] (b) (6)  
**Sent:** Friday, February 28, 2020 8:22 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Collins, Francis (NIH/OD) [E] (b) (6); Schwetz, Tara (NIH/OD) [E]  
(b) (6) >  
**Subject:** OSTP call

Tony,

Tara and I took the call with Kelvin Droegemeier, France Cordova (NSF), and Paul Dabbar (DOE).



Please let me know if you need anything else. (Tara -if I left anything out please add).

Larry



Sent from my iPhone

**From:** (b) (6)  
**Sent:** Fri, 28 Feb 2020 19:48:05 -0500  
**To:** Harris, Kara (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E]  
**Subject:** Fwd: Coronavirus on surfaces

Public inq pls

Sent from my iPhone

Begin forwarded message:

**From:** Deborah Greene (b) (6)  
**Date:** February 28, 2020 at 7:38:44 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>  
**Subject:** **Coronavirus on surfaces**

Hello Dr Fauci,

I am trying to find out how long the coronavirus can remain infectious on the surface of an object handled by someone with the virus.

My concern is with purchasing items for my jewelry shop that come from China , South Korea, and Turkey.

I have not been able to find anything that addresses this question and hope you can clarify this for me. Thank you.

Sincerely yours,  
Deborah Greene

Sent from my iPhone

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 23:18:10 +0000  
**To:** Casseti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Corona Virus  
**Attachments:** US Biotest Letter re COVID-19 Fauci, A.pdf, Coronavirus- (b) (4)  
Rationale.pptx, US Biotest Regulatory History of (b) (4).pdf, US Biotest COVID-19  
(b) (4) References.pdf

Please handle. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Samantha Mauro (b) (6) >  
**Sent:** Friday, February 28, 2020 6:11 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Gere diZerega (b) (6) >  
**Subject:** Corona Virus

Dear Dr. Fauci:

(b) (4)





Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,

Gere diZerega MD  
Professor  
Keck School of Medicine  
University of Southern California  
And  
President and CEO  
US Biotest, LLC  
San Luis Obispo, CA  
(b) (6)

Kathleen Rodgers PhD  
Professor, Department of Pharmacology  
College of Medicine  
Center for Innovation in Brain Sciences  
Associate Director of Translational Neurosciences  
University of Arizona  
Tucson, AZ  
(b) (6)

**From:** (b) (6)  
**Sent:** Fri, 28 Feb 2020 16:54:13 -0500  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** Fwd: Urgent Email/Strategy to attack 2019-nCoV coronavirus  
**Attachments:** Nucleotide\_Analogues\_as\_Inhibitors of SARS-CoV Polymerase\_2\_28\_2020.pdf, ATT00001.htm, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.pdf, ATT00002.htm

Pls handle

Sent from my iPhone

Begin forwarded message:

**From:** Jingyue Ju (b) (6)>  
**Date:** February 28, 2020 at 4:46:04 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)  
**Cc:** "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6), "directorsincoming@cdc.gov" <directorsincoming@cdc.gov>, "Redfield, Robert R. (CDC/OD)" (b) (6), "Davis, Mindy (NIH/NIAID) [E]" (b) (6), "Eakin, Ann (NIH/NIAID) [E]" <(b) (6)>, "Stemmy, Erik (NIH/NIAID) [E]" (b) (6), "Sciotti, Rick (NIH/NIAID) [E]" (b) (6), "Schiltz, Helen (NIH/NIAID) [E]" (b) (6), "Krafft, Amy (NIH/NIAID) [E]" (b) (6)>  
**Subject: Re: Urgent Email/Strategy to attack 2019-nCoV coronavirus**

Dear Dr. Fauci,

Following my previous email regarding our work on developing strategies to attack the 2019-nCoV coronavirus, I am attaching in this email our experimental results demonstrating that 2 nucleotide analogues are inhibitors of the SARS-CoV polymerase. Since the SARS-CoV polymerase has over 96% similarity to the polymerase from SARS-CoV-2, we expect that the nucleotide analogues, 2'-F,Me-UTP and 3'-F-dTTP, will also inhibit the SARS-CoV-2 polymerase.

At this point, it is imperative that the prodrug forms (one is Sofosbuvir that is FDA approved for HepC) of these molecules begin immediate in vitro testing with infected cells (similar to the studies carried out for Remdesivir and chloroquine in the Cell Research article at the link, <https://www.nature.com/articles/s41422-020-0282-0>; PDF file of the article also attached) followed by animal testing trials ASAP. Since we do not have access to the SARS-CoV-2 viral strains, we need your assistance to identify resources at the NIH laboratories to embark on this next step



investigation ASAP. We can provide the prodrugs to the labs at NIH that you identify for carrying out these studies. In view of the worldwide SARS-CoV-2 emergency, we'd like your assistance in getting this off the ground ASAP.

I can be reached any time at (b) (6)

All the best,

Jingyue Ju, Ph.D.  
Samuel Ruben-Peter G. Viele Professor of Engineering  
Professor of Chemical Engineering and Pharmacology  
Director, Center for Genome Technology & Biomolecular Engineering  
Columbia University  
Northwest Corner Building, Room 1000M1  
550 West 120th Street  
New York, NY 10027  
Phone:

(b) (6) wrote:

Dear Drs. Fauci and Redfield,

Scientists in my laboratory at Columbia University are actively engaged in design strategies to cope with the new strain of coronavirus, 2019-nCoV, which has caused a global public health emergency. We have embarked on a project entitled "Nucleotide Analogues as Inhibitors of Viral Polymerases". We provide a summary of this work below.

Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3'-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.

Please let me know if you would like to receive the full manuscript.

Thank you very much for your consideration.

Sincerely,

Jingyue

Jingyue Ju, Ph.D.

Samuel Ruben-Peter G. Viele Professor of Engineering

Professor of Chemical Engineering and Pharmacology

Director, Center for Genome Technology & Biomolecular Engineering

Columbia University

Northwest Corner Building, Room 1000M1

Phone:

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 21:27:35 +0000  
**To:** Casetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Corona Virus  
**Attachments:** US Biotest Regulatory History of (b) (4).pdf, US Biotest COVID-19 (b) (4) References.pdf, US Biotest Letter re COVID-19 Fauci, A.pdf

Please take a look and handle if necessary.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Gere diZerega <(b) (6)>  
**Sent:** Friday, February 28, 2020 3:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Gere diZerega <(b) (6)>  
**Subject:** Corona Virus

Dear Dr. Fauci:

(b) (4)

Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,  
Gere

**GERE DIZEREGA**  
**PRESIDENT AND CEO**  
**US BIOTEST, INC.**

231 BONETTI DRIVE, SUITE 240  
SAN LUIS OBISPO, CA 93401-7310  
TEL: (b) (6) ✦ FAX: 805.595.1350

*The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.*



**From:** (b) (6)  
**Sent:** Fri, 28 Feb 2020 13:41:02 -0500  
**To:** Casseti, Cristina (NIH/NIAID) [E]  
**Subject:** Fwd: As bad as measles?

Please handle

Begin forwarded message:

**From:** Ed Charlton <(b) (6)>  
**Date:** February 28, 2020 at 1:07:32 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)  
**Subject:** As bad as measles?

Dr Fauci, you are the pre-eminent infectious disease physician in the world. I'm concerned the public has lost perspective on COVID-19. At this point, it would seem the  $r_0$  and CFR are more similar to rubeola than they are to Ebola. Can we remind the public of that? Communicating that influenza will kill more Americans than SARS-2 hasn't gained traction. Might someone like yourself or Dr Carson communicate more strongly to the public the risks compared to other viruses they are familiar with, like rubeola, rubella, varicella, etc?

**From:** (b) (6)  
**Sent:** Fri, 28 Feb 2020 13:39:34 -0500  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** Fwd: Experimental vaccine for Covid-19

Please respond. Mention risk of enhancement

Begin forwarded message:

**From:** "William J. Buikema" (b) (6) >  
**Date:** February 28, 2020 at 1:08:50 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >  
**Subject:** Experimental vaccine for Covid-19

Dear Dr. Fauci,

I understand the need for the various stages of testing a new experimental vaccine, but in listening to you give a timeline for any new vaccine for the corona virus, it struck me that perhaps a modified approach might be considered. Why not allow early use of a vaccine that has passed a phase 1 safety testing, similar to what was done for the Ebola vaccines. If a vaccine is shown to be reasonably safe, why not allow its use in more at-risk people (elderly, smokers) before phase 2 trials are finished. It could also be helpful as with the Ebola vaccines to prevent transmission in hot spots of community acquired infections. There doesn't seem to be much downside compared to the potential for preventing many more deaths than was seen in the Ebola situation.

Sincerely yours,

Bill Buikema

William J. Buikema, PhD, Research Associate  
Technical Director, DNA Sequencing & Genotyping Core  
University of Chicago, KCBD 1230H&I  
900 E 57th Street, Chicago, IL 60637  
773-702-1088, cancer-seqbase.uchicago.edu

**From:** (b) (6)  
**Sent:** Fri, 28 Feb 2020 11:21:22 -0500  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Fwd: coronavirus vaccine story?

Sent from my iPhone

Begin forwarded message:

**From:** Olga Khazan <[olga@theatlantic.com](mailto:olga@theatlantic.com)>  
**Date:** February 28, 2020 at 11:09:49 AM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>  
**Subject:** coronavirus vaccine story?

Hi Tony -- It's Olga at the Atlantic ... I'm hearing that there's a coronavirus vaccine trial in the works at the VTEU sites. We'd love to tell the story, but everyone is directing me to you and NIAID. Would you be able to talk with me about this today for a story? My cell is (b) (6), and my desk is 202-266-7387.

Thanks,  
Olga

--  
Olga Khazan  
Staff Writer  
The Atlantic  
[olga@theatlantic.com](mailto:olga@theatlantic.com)  
cell: (b) (6)

**From:** [REDACTED] (b) (6)  
**Sent:** Fri, 28 Feb 2020 08:59:04 -0500  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Fwd: MEDIA INQUIRY

Sent from my iPhone

Begin forwarded message:

**From:** Lemonov Alexander <anlemonov@rttv.ru>  
**Date:** February 28, 2020 at 8:13:34 AM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)>  
**Subject:** MEDIA INQUIRY

Dear Dr. Fauci,

My name is Alexander Lemonov, I am a producer for RT International TV channel.

I would like to invite you to appear on "Worlds Apart", RT's 26-minute uncensored one-on-one interview show.

We would like to talk about the spread of the COVID-19 coronavirus, the response measures countries should take, the world's general preparedness for pandemics, COVID-19's possible consequences for other areas: healthcare, economy, security, etc.

Would you be available?

FYI: "Worlds Apart" is an uncensored interview show that is aired on RT International, RT America, RT UK, and RT Russia (in Russian).

All episodes get featured on RT social media accounts, watched by their multimillion international crowd.

Our guests endorse widely different views, and we are happy to broadcast different opinions. Here's the link to our show: <https://www.rt.com/shows/worlds-apart-oksana-boyko/>

"Worlds Apart" has featured:

businessman Richard Branson, lawyer Alan Dershowitz, former Israeli FM Tzipi Livni, UN Secretary General Antonio Guterres, UN Women Executive Director Phumzile Mlambo-Ngcuka, former Prime Minister of Italy Giuliano Amato, former U.S. State Department coordinator for JCPOA Jarrett Blanc, foreign minister of Iran Javad Zarif, adviser on international affairs to Supreme Leader of Iran Ali Akbar Velayati, former chief economist of the World Bank Anne Krueger, Secretary General of OSCE Thomas Greminger, special adviser to PM of Japan Tomohiko Taniguchi, senior fellow at the Brookings Institution Mike O'Hanlon, etc.

I would appreciate a reply.



Kind regards,  
Alexander Lemonov  
Producer  
"Worlds Apart", RT  
Mobile: [REDACTED] (b) (6)  
Office: +7 (499) 75-000-75, ext. 2492

Александр Лемонов  
Продюсер  
"Worlds Apart", RT  
Моб.: [REDACTED] (b) (6)  
Раб.: +7 (499) 75-000-75, доб. 2492



[rt.com](http://rt.com)



[twitter.com/rt.com](https://twitter.com/rt.com)

[facebook.com/RTnews](https://facebook.com/RTnews)

[youtube.com/user/RussiaToday](https://youtube.com/user/RussiaToday)

[plus.google.com/102728491539958529040/posts](https://plus.google.com/102728491539958529040/posts)

**CONFIDENTIALITY:**

The information contained in this transmission is intended exclusively for the proper use by the intended addressees and may contain confidential and/or privileged material. Any views expressed in this transmission are those of the individual sender, except where the transmission states otherwise and the sender being authorised appropriately. Any review, dissemination and other use of this information, as well as any action in reliance upon this information by persons and/or entities other than the intended addressees is prohibited. If you received this information in error, please note that no confidentiality or privilege is waived or lost by any mis-transmission. Note that we monitor e-mails sent or received. Further communication will signify your consent to the above.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 11:50:04 +0000  
**To:** Kaplan, Edward H  
**Subject:** RE: Coronavirus

Ed:

Thanks for the note. Great to hear from you. I hope that all is well.  
Best regards,  
Tony

-----Original Message-----

From: Kaplan, Edward H <[REDACTED] (b) (6)>  
Sent: Thursday, February 27, 2020 10:42 AM  
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>  
Subject: RE: Coronavirus

Hi again Tony. Here's a link to a non-technical explanation of the paper I shared with you earlier:

<https://insights.yale.edu/insights/new-outbreaks-of-coronavirus-can-be-halted-with-isolation-measures-according-to-study>

I have seen predictions stating that upwards of 30% of the world's population will be infected, but I don't see this happening. What I do see are lots of local outbreaks from imported cases, some larger than others, but all heading towards containment. I find Israel to be an interesting test case. A group of infected Korean tourists who visited the country only tested positive for coronavirus after their return to Korea, joining the large outbreak that has been reported there. The itinerary of their travel group has been made public so that retrospectively, Israeli public health officials could ascertain who was exposed where and when (see [https://www.health.gov.il/English/News\\_and\\_Events/Spokespersons\\_Messages/Pages/23022020\\_1.aspx](https://www.health.gov.il/English/News_and_Events/Spokespersons_Messages/Pages/23022020_1.aspx)). Already 1,600 Israelis have been quarantined on account of possible exposure. It has been twelve days since this group of tourists returned to Korea, and no new infections have been reported in Israel associated with this group (there are two Israelis who were infected on the Diamond Princess cruise ship, and one infected while in Italy). See <https://www.ynetnews.com/article/H1nXPa7E8>. It will be interesting (and important) to see how many new infections are detected in the days ahead, and if such new infections are found among those already under preventive watch.

Nonetheless I totally concur with preparing as if major transmission will occur. Much better to err by over- rather than under- preparing (a familiar perspective from those bygone smallpox debates).

Finally, a reporter asked me yesterday afternoon what I wanted the President to say last night. Here was my response:

In a sober way summarize the facts of the outbreak, state that the US has an excellent preparedness team between CDC and NIH, that at the advice of this team travel restrictions and quarantine measures have already been enacted, but as of now the public is at very low risk of infection. Still, citizens should go to [cdc.gov](http://cdc.gov) now to learn from our experts how to prepare in the event that more extreme measures are needed, stay abreast of the situation here and abroad and follow the advice of our experts, get a flu shot (!), and know that the US has a very strong public health system that can withstand this challenge.

Anyway, just wanted to share all this with you. Keep up the good work and good luck with the vaccine research, Ed

-----Original Message-----

From: Kaplan, Edward H  
Sent: Saturday, February 8, 2020 10:13 PM  
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)

Subject: Coronavirus containment modeling

Dear Dr. Fauci,

It has been many years since we corresponded regarding smallpox bioterrorism and vaccination control.

The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate below epidemic threshold - but the key is rapid detection of infected persons. Also discussed are some ideas for alleviating congestion in the hospital. I hope that you find it helpful.

Best, Ed Kaplan

Edward H. Kaplan, Ph.D.

William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520-8200

Phone: (b) (6)

e-mail: (b) (6)

<https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Ffaculty.som.yale.edu%2FEdKaplan%2F&amp;data=02%7C01%7Cedward.kaplan%40yale.edu%7Cb00119dedbe24bc635d208d7bb9b24c7%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637184147315834392&amp;sdata=11LC4xAuAc%2BjdNuG%2BA2oGxcS9LS95PoQRi7yO0dLRd0%3D&amp;reserved=0>



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 11:25:43 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Coronavirus update for your upcoming Keystone Symposia meeting

FYI

---

**From:** Allison Ogdon <AllisonO@keystonesymposia.org>  
**Sent:** Friday, February 28, 2020 12:10 AM  
**To:** Allison Ogdon <AllisonO@keystonesymposia.org>  
**Cc:** Heidi Daetwyler <HeidiD@keystonesymposia.org>  
**Subject:** Coronavirus update for your upcoming Keystone Symposia meeting  
**Importance:** High



Greetings,

**In light of the current coronavirus situation, we would like to provide an update on your upcoming Keystone Symposia conference.**

The health and safety of our meeting attendees and speakers is our top priority, and we are carefully monitoring the coronavirus situation around the world to ensure we take the necessary precautions as recommended by healthcare providers and public health organizations.

Currently, ***your meeting will proceed as scheduled***, and we will contact you immediately if anything changes. Decisions will be made on a moment to moment basis, as new information becomes available. We assure you that the leadership team at Keystone Symposia is closely monitoring global developments and will take swift action to ensure the health and safety of all meeting participants.

As a speaker, you hold a very special role at the meeting as a field leader. We very much appreciate your contribution to both the scientific program, and the community of luminary scientists who will convene to direct the future of the field. Your presentation will be a highlight for many attendees, and your insights will inspire others to take on new and innovative directions in their own work. This is the essence of Keystone Symposia -- convening communities of leading scientists to inspire each other to advance biomedicine, and this would not be possible without your engagement.

We realize the current situation may add some inconveniences to travel at this time, but we also remind you that each and every one of our speakers is hand-selected by a committee of the world's leading experts to represent their field at the meeting. You are among a very select few to receive this honor.



The meeting organizers, and our team at Keystone Symposia, have put a great deal of time and effort over the last two years into designing the program, and your presentation is a key part of that. We hope you will take these thoughts into consideration as the meeting approaches.

While this is a time we must all be vigilant about public health measures, we are reminding conference attendees that this is also a time to remain calm, rational and scientific in addressing the situation. We encourage you to engage with your fellow colleagues at the meeting as you normally would, to forge new collaborations and novel ideas that will drive your research and the field in innovative and fruitful directions. At the meeting, we are providing the following suggestions based on recommendations from the National Foundation of Infectious Disease:

- ***The best way to protect yourself against COVID-19 is similar to how you would take precautions against the cold or flu.*** Wash your hands often using soap and water for at least 20 seconds. Cover your cough or sneeze with a tissue or the crook of your elbow rather than your hands.
- ***There is no need to wear a face mask if you are well and do not have symptoms***—masks protect the sick from spreading germs but will not prevent you from getting sick.
- ***Do not assume that anyone of Asian descent is more likely to have coronavirus***—do not forget about the importance of inclusivity and evidence-based information.

Again, we thank you for your contributions and commitment to Keystone Symposia and wish for a very successful and inspiring meeting.

Sincerely,



Deborah L. Johnson, Ph.D.  
President and Chief Executive Officer  
Keystone Symposia on Molecular and Cellular Biology

KEYSTONE  SYMPOSIA™  
on Molecular and Cellular Biology  
*Accelerating Life Science Discovery*

**INCLUDE**  
DIVERSITY IN THE SCIENTIFIC WORKFORCE

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)  
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)  
970.262.1230 | 800.253.0685 | [www.keystonesymposia.org](http://www.keystonesymposia.org)  
Visit [virtual.keystonesymposia.org](http://virtual.keystonesymposia.org) to view our digital content.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:25:27 +0000  
**To:** Kline, Lydia (NIH/OD) [E]  
**Subject:** RE: thank you

Lydia:

Thanks for your kind note.

Best regards,

Tony

---

**From:** Kline, Lydia (NIH/OD) [E] (b) (6) >  
**Sent:** Thursday, February 27, 2020 9:45 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** thank you

Tony,

I'm sure many people are telling you this, but I wanted to add my thanks to you for everything you do to keep the world safer and healthier! You are doing an incredible job (as always) out there with coronavirus.

Best,  
Lydia

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:23:12 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: invitation to speak on COVID 19 at the International ATS Conference in May  
**Attachments:** image001.png, image003.png

Sorry no

---

**From:** Fennelly, Kevin (NIH/NHLBI) [E] (b) (6) >  
**Sent:** Thursday, February 27, 2020 9:02 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** invitation to speak on COVID 19 at the International ATS Conference in May

Dear Dr. Fauci,

I don't believe that we've formally met, but I have seen you frequently on 5SE as I admit patients there and often participate in the ward rounds. I am an AI on several of Steve Hollands protocols, and I often help with the drug-resistant TB cases. I have been at the NIH now for over 4 years, although I still feel like the new guy on the block! Most of my career has been focused on quantifying the infectious aerosols generated by TB patients. I am very involved in the leadership of the American Thoracic Society (ATS) as the Past Chair of the Assembly on Pulmonary Infections and TB. I am writing to invite you to be a keynote speaker at a special Scientific Session being added to our International Conference May 16-20 due to the emerging pandemic of COVID-19. The exact time and data are not yet known, but the conference is relatively close in Philadelphia. This would be an opportunity to address and educate global academic leaders in pulmonary and critical medicine, infectious diseases, and public health. We usually have over 15,000 attendees at the ATS meeting. I am attaching the email string below to give you an idea of other speakers being considered.

I can only imagine how busy you must be now, so I apologize if this invitation is a distraction or a nuisance. And I would certainly understand if you are unable to join us given the demands on your time, but we would be absolutely delighted if you could speak.

Please feel to call or contact me at any time with questions or comments.

Sincerely,  
Kevin Fennelly  
Mobile (b) (6)

Kevin P Fennelly, MD, MPH, ATSF  
Senior Research Clinician  
Laboratory of Chronic Airway Infection  
Pulmonary Branch  
Division of Intramural Research  
National Heart, Lung, and Blood Institute (NHLBI)  
National Institutes of Health (NIH)



Building 10, Room 5-1421  
10 Center Drive  
Bethesda, MD 20892

---

**From:** Saukkonen, Jussi J (b) (6) >  
**Sent:** Wednesday, February 26, 2020 7:15 PM  
**To:** Dela Cruz, Charles (b) (6) >  
**Cc:** Kristina Crothers (b) (6) >; Nahid, Payam (b) (6);  
Saukkonen, Jussi <(b) (6)>; Maria Novozhilova (b) (6); Miriam  
Rodriguez (b) (6); Fennelly, Kevin (NIH/NHLBI) [E]  
(b) (6)  
Hicks, Lauri (CDC/DDID/NCEZID/DHQP)  
(b) (6) Evans, Scott (b) (6) >; Yeligar,  
Samantha (b) (6) McGinniss, John E  
(b) (6) >  
**Subject:** Re: PI-TB Executive Committee Call

This looks like a great program. Hope you can get these speakers who will be in demand.

On Feb 26, 2020, at 2:44 PM, Dela Cruz, Charles (b) (6) wrote:


Thank you all for your great suggestions...

Here is a possible Agenda for the Special Session on Coronavirus.  
Ideally, we should have some ATS attendees to be speakers. If anyone knows possible candidate, please let us know. I also know that ATS would like to encourage some high profile speakers if possible. Someone from CDC, NIAID, etc.

Please let us know additional suggestions.  
I highlighted bold are possible speakers.  
We will need to wait until the ATS BOD this week to get the go ahead to invite the speakers.

---

(b) (4)





(b) (6) >

**Subject:** Re: PI-TB Executive Committee Call

Hi - these are great suggestions.

(b) (4)

(b) (4)

Kristina

---

**From:** Saukkonen, Jussi J (b) (6)

**Sent:** Tuesday, February 25, 2020 9:02:43 AM

**To:** Nahid, Payam

**Cc:** Dela Cruz, Charles; Saukkonen, Jussi; Crothers, Kristina; Maria Novozhilova; Miriam Rodriguez; (b) (6); Kevin P. Fennelly, MD; (b) (6)

(b) (6); Evans, Scott; Yeligar, Samantha M.;

(b) (6); McGinniss, John E

**Subject:** Re: PI-TB Executive Committee Call

These would be excellent speakers to also try to get!



> On Feb 25, 2020, at 11:50 AM, Nahid, Payam [REDACTED] (b) (6) wrote:

>

> Agree, these are excellent suggestions. An FYI below on what CROI has assembled for ad hoc session on COVID-19:



>

> -----

> Payam Nahid, MD, MPH

> Professor of Medicine

> University of California, San Francisco

> Associate Director, Clinical Trials Operations, UCSF Office of Research

> Medical Director, UCSF CTSI Trials Innovation Network (TIN)

> Director, UCSF Center for Tuberculosis (<http://tb.ucsf.edu>)

## [UCSF Center for Tuberculosis | UCSF Center for TB](#)

[tb.ucsf.edu](http://tb.ucsf.edu)

>

> Zuckerberg San Francisco General Hospital

> Division of Pulmonary & Critical Care Medicine

> 1001 Potrero Avenue, Room 5K1

> San Francisco, CA 94110

> Email: [REDACTED] (b) (6)

> UCSF Profile: <http://profiles.ucsf.edu/payam.nahid>

## [Payam Nahid | UCSF Profiles](#)


[profiles.ucsf.edu](http://profiles.ucsf.edu)

Payam Nahid's profile, publications, research topics, and co-authors

> Tel: [REDACTED] (b) (6)

> Pronouns: he, him, his

>  
>  
>  
> On 2/25/20, 6:47 AM, "Dela Cruz, Charles" (b) (6) wrote:  
>  
> Thanks Jussi for your great suggestions. We will try to incorporate these into the final session.  
> Much appreciated  
> Charles  
>  
>  
>  
> -----  
> Charles S. Dela Cruz, MD, PhD  
> Associate Professor  
> Section of Pulmonary, Critical Care and Sleep Medicine  
> Department of Internal Medicine  
> Department of Microbial Pathogenesis  
> Director, Center of Pulmonary Infection Research and Treatment (CPIRT)  
> Yale University  
> 300 Cedar Street TAC S441-D  
> New Haven, CT 06513  
> Phone: (b) (6)  
> FAX: 203 785-5952  
>  
> Email: (b) (6)  
> Faculty profile: [https://urldefense.proofpoint.com/v2/url?u=http-3A\\_medicine.yale.edu\\_intmed\\_pulmonary\\_people\\_charles-5Fdelacruz.profile&d=DwIGaQ&c=iORugZIs2LIYyCAZRB3XLg&r=XoHvlyApUj67iV1KyA1zSg&m=OCAE5v-43B0vEiVlnTNd-DXvFYATijFpvJftbDe3o4&s=XbJr53zMi1g0yYn-iXh9t9\\_vBPfjcNC8h-iRJ2lihVk&e=](https://urldefense.proofpoint.com/v2/url?u=http-3A_medicine.yale.edu_intmed_pulmonary_people_charles-5Fdelacruz.profile&d=DwIGaQ&c=iORugZIs2LIYyCAZRB3XLg&r=XoHvlyApUj67iV1KyA1zSg&m=OCAE5v-43B0vEiVlnTNd-DXvFYATijFpvJftbDe3o4&s=XbJr53zMi1g0yYn-iXh9t9_vBPfjcNC8h-iRJ2lihVk&e=)



[Charles Dela Cruz, MD, PhD < Pulmonary, Critical Care and Sleep Medicine](#)

[urldefense.proofpoint.com](https://urldefense.proofpoint.com)

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine

---

and is currently an Associate  
Professor at Yale University in the

---

> Lab website: [https://urldefense.proofpoint.com/v2/url?u=http-3A\\_medicine.yale.edu\\_lab\\_delaacruz\\_index.aspx&d=DwIGaQ&c=iORugZIs2LIYyCAZRB3XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATljFpvUftbDe3o4&s=F7cVzfOPw5tmgLz95Y984or0dPHCoEYBNsv\\_ip7GA2g&e=](https://urldefense.proofpoint.com/v2/url?u=http-3A_medicine.yale.edu_lab_delaacruz_index.aspx&d=DwIGaQ&c=iORugZIs2LIYyCAZRB3XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATljFpvUftbDe3o4&s=F7cVzfOPw5tmgLz95Y984or0dPHCoEYBNsv_ip7GA2g&e=)

---

## [Dela Cruz Lab](#)

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

---

> CPIRT website: [cpirt.yale.edu](http://cpirt.yale.edu)


>

>

>

>

>



> On 2/25/20, 9:34 AM, "Saukkonen, Jussi"  (b) (6) wrote:

>

> Great!

(b) (4)






[First US MERS-CoV Cases Underscore Need for Preparedness | Global Health | JAMA | JAMA Network](#)

[urldefense.proofpoint.com](http://urldefense.proofpoint.com)

Confirmation of the first 3 US cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection highlighted the importance of preparedness plans and infection control policies for hospitals and other facilities in dealing with a potentially dangerous infectious disease.







[2019 Novel  
Coronavirus—Important  
Information for  
Clinicians | Global  
Health | JAMA | JAMA  
Network](#)

[urldefense.proofpoint.com](http://urldefense.proofpoint.com)

This Viewpoint summarizes the epidemiology and clinical features of 2019-nCoV infection and reviews CDC criteria to guide evaluation and management of patients with possible infection.

(b) (4)



> -----Original Message-----

> From: Dela Cruz, Charles (b) (6)

> Sent: Monday, February 24, 2020 9:49 PM

> To: Crothers, Kristina (b) (6)>; Maria Novozhilova (b) (6)>

> Cc: Miriam Rodriguez (b) (6); Kevin P. Fennelly, MD (b) (6)>; Nahid, Payam (b) (6)

> (b) (6)>; Evans, Scott

> (b) (6)>; Yeligar, Samantha M. (b) (6)

> (b) (6)>; Saukkonen, Jussi (b) (6)

McGinniss, John E (b) (6)

> Subject: [EXTERNAL] Re: PI-TB Executive Committee Call

>

> Dear colleagues

>

> Hope all is well.

>

> As part of ATS 2020 in May, PITB Programming has been requesting to see if there would be a venue for a coronavirus session.

>

> The ICC chair and ATS was able to seek out a possible forum for a Special Session on Coronavirus on the Monday Afternoon during ATS.


>

> Payam and I have been discussing a possible session title, content and speakers.

>

> The session title could be --


>



>  
> Many thanks  
> Charles

>  
>  
> -----  
> Charles S. Dela Cruz, MD, PhD  
> Associate Professor  
> Section of Pulmonary, Critical Care and Sleep Medicine Department of Internal Medicine  
> Department of Microbial Pathogenesis Director, Center of Pulmonary Infection Research and  
> Treatment (CPIRT) Yale University  
> 300 Cedar Street TAC S441-D  
> New Haven, CT 06513  
> Phone: (b) (6)  
> FAX: 203 785-5952

>  
> Email: (b) (6)  
> Faculty profile: [https://urldefense.proofpoint.com/v2/url?u=https-3A\\_nam05.safelinks.protection.outlook.com-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Fintmed-252Fpulmonary-252Fpeople-252Fcharles-5Fdelacruz.profile-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bsdata-3DQWWL&cD0cYtHaxgilDZfU7dywmTyCbpP54bIOO2RpHs-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZls2LIYyCAZR83XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATIjFpvUftbDe3o4&s=TVWeA9SztUxTEK8J5yHFcOkt3CyArZWdsYQDZPgeuEQ&e=](https://urldefense.proofpoint.com/v2/url?u=https-3A_nam05.safelinks.protection.outlook.com-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Fintmed-252Fpulmonary-252Fpeople-252Fcharles-5Fdelacruz.profile-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bsdata-3DQWWL&cD0cYtHaxgilDZfU7dywmTyCbpP54bIOO2RpHs-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZls2LIYyCAZR83XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATIjFpvUftbDe3o4&s=TVWeA9SztUxTEK8J5yHFcOkt3CyArZWdsYQDZPgeuEQ&e=)



[Charles Dela Cruz, MD,  
PhD < Pulmonary,  
Critical Care and Sleep  
Medicine](#)

[urldefense.proofpoint.com](http://urldefense.proofpoint.com)

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Associate Professor at Yale University in the

> Lab website: [https://urldefense.proofpoint.com/v2/url?u=https-3A\\_nam05.safelinks.protection.outlook.com\\_-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Ftab-252Fdelacruz-252Findex.aspx-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bsdata-3DaUEJSTgiaCXmTQiuAB0K0YrMiqFxdd2HiPhGuq8Psig-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZls2LIYyCAZRB3XLg&r=XoHvYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVlnTnd--DXvFYATlJFpvUftbDe3o4&s=s6rnKnYlqiuUr8OII\\_HRKYfFhvJwdc4\\_t9rmpZzqixY&e=](https://urldefense.proofpoint.com/v2/url?u=https-3A_nam05.safelinks.protection.outlook.com_-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Ftab-252Fdelacruz-252Findex.aspx-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bsdata-3DaUEJSTgiaCXmTQiuAB0K0YrMiqFxdd2HiPhGuq8Psig-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZls2LIYyCAZRB3XLg&r=XoHvYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVlnTnd--DXvFYATlJFpvUftbDe3o4&s=s6rnKnYlqiuUr8OII_HRKYfFhvJwdc4_t9rmpZzqixY&e=)

[Dela Cruz Lab](#)

[urldefense.proofpoint.com](http://urldefense.proofpoint.com)

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: [cpiirt.yale.edu](http://cpiirt.yale.edu)

>  
>  
>  
>



>  
> On 2/22/20, 7:47 PM, "Crothers, Kristina" <[REDACTED]> (b) (6) wrote:  
>  
> Hi all - we need to reschedule the call as both Rachel and I will be traveling to the ATS board meeting next Wednesday. Please let me and Maria know if you could join a call Wednesday March 4 at 4pm eastern instead.  
> Kristina  
>  
> Sent from my iPhone  
>  
>> On Feb 21, 2020, at 12:20 PM, Maria Novozhilova <[REDACTED]> (b) (6) > wrote:  
>>  
>>  
>> <PI-TB Executive Committee Call>  
>  
> \_\_\_\_\_  
>  
> Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.  
>  
>  
>  
>  
>  
>



NIH-001207

CAPRT





**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:21:24 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Invitation to Spanih meeting

RSVP sorry no.

---

**From:** Jose Alcamí Pertejo <ppalcamí@isciii.es>  
**Sent:** Thursday, February 27, 2020 10:16 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Jose Alcamí Pertejo <ppalcamí@isciii.es>  
**Subject:** Invitation to Spanih meeting

Dear Dr Fauci,

Hope this mail finds you well. We had the opportunity to meet in Madrid during the R4P meeting. I was the local chair of the Conference and had the privilege of introducing your talk to the plenary.

I would like to invite you as plenary speaker to the meeting of the Spanish AIDS Society (GESIDA) that will take place in Málaga, Spain next 30<sup>th</sup> November 2020. GESIDA Congress is the most important HIV national meetings in Spain that brings together the full "HIV Community" including clinicians, basic researchers, experts in epidemiology and public health and member from NGOs and patients' associations. Overall 700 attendees are expected to come to the meeting.

We would love to have you as a speaker in the Opening Plenary Session in evening the 30<sup>th</sup> November. Your challenging articles regarding the strategies to end the HIV epidemic in the United States, will be a great topic to be addressed in such session and an inspiration to Spanish researchers. If you prefer to talk about a different topic as the co-morbidities scenario in HIV infection it will be welcome too.

We would be more than happy if you could participate in this meeting.

If know your agenda is always full, even more these days with the current Coronavirus outbreak,



but if you could accept this invitation I think this can represent a real boost in the fight against HIV epidemics in Spain, a field in which the Spanish AIDS Society is strongly committed.

It would be wonderful if we can have you as a speaker.

Best wishes

Jose Alcamí

\*\*\*\*\* AVISO LEGAL \*\*\*\*\* Este mensaje electrónico está dirigido exclusivamente a sus destinatarios, pudiendo contener documentos anexos de carácter privado y confidencial. Si por error ha recibido este mensaje y no se encuentra entre los destinatarios, por favor no use, informe, distribuya, imprima o copie su contenido por ningún medio. Le rogamos lo comunique al remitente y borre completamente el mensaje y sus anexos. El Instituto de Salud Carlos III no asume ningún tipo de responsabilidad legal por el contenido de este mensaje cuando no responda a las funciones atribuidas al remitente del mismo por la normativa vigente.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:13:52 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: David Rubenstein's invitation to Dr. Fauci

I always like to do things with David Rubenstein

---

**From:** Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Sent:** Thursday, February 27, 2020 12:19 PM  
**To:** NIAID OD AM <NIAIDODAM@niaid.nih.gov>  
**Subject:** FW: David Rubenstein's invitation to Dr. Fauci

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
[REDACTED] (b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Mary Brady <[MBrady@economicclub.org](mailto:MBrady@economicclub.org)>  
**Sent:** Wednesday, February 26, 2020 6:07 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Cc:** [REDACTED] (b) (6); Judi Irastorza <[Judi.Irastorza@economicclub.org](mailto:Judi.Irastorza@economicclub.org)>  
**Subject:** David Rubenstein's invitation to Dr. Fauci

Patricia,

David Rubenstein asked that we reach out to you in an effort to schedule an Economic Club of Washington event that would feature Dr. Fauci in a conversation with David on COVID-19. It is my understanding that David had a similar interview with Dr. Fauci in the last week or so.

Below are several dates from David's calendar for your consideration.

Wednesday, April 22 – Breakfast

Tuesday, April 28 – Breakfast or lunch  
Tuesday, May 5 – Breakfast or Lunch  
Friday, May 15 – Lunch

Additionally, I have attached an invitation letter from Mr. Rubenstein to Dr. Fauci for your convenience. The Economic Club has the ability to turn around an event in a relatively short period of time. As you may recall, our events typically take place at breakfast, lunch or dinner, at downtown Washington, D.C. hotels. Events that feature a prominent world leader, such as Dr. Fauci, generally attract a select audience of over 500 members and guests from among Washington's business and government leaders, as well as the diplomatic corps.

We understand the complexities and constraints of Dr. Fauci's schedule and can be responsive to his needs. If none of the dates above work with Dr. Fauci's schedule, please suggest some that will and we will work with David to confirm a date and begin the process. I have copied Judi Irastorza, who I believe you have worked with in the past, and she will coordinate anything you need.

Sincerely,  
Mary

**Mary C. Brady**

Executive Director

The Economic Club of Washington, D.C.

1601 K Street NW, Suite 210, Washington, DC 20006

Office: (202) 481-3260 | Mobile: (b) (6)

[mbrady@economicclub.org](mailto:mbrady@economicclub.org)

[Our Sponsors](#) | [www.EconomicClub.org](http://www.EconomicClub.org)

[@TheEconomicClub](#) | [LinkedIn](#) | [YouTube](#)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:10:35 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Invitation to join Scientific Advisory Board

Please handle.

---

**From:** Ajay Gupta <[REDACTED] (b) (6)>  
**Sent:** Thursday, February 27, 2020 1:04 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Subject:** Re: Invitation to join Scientific Advisory Board

Hi Dr. Fauci,

just a quick question. [REDACTED] (b) (4)

[REDACTED]

thanks,

Ajay

---

**From:** "Fauci, Anthony (NIH/NIAID) [E]" <[REDACTED] (b) (6)>  
**Date:** Monday, February 17, 2020 at 3:59 AM  
**To:** Ajay Gupta <[REDACTED] (b) (6)>  
**Subject:** RE: Invitation to join Scientific Advisory Board

Thanks for the note. My position in the US Government does not allow me to join such Boards.

---

**From:** Ajay Gupta <[REDACTED] (b) (6)>  
**Sent:** Sunday, February 16, 2020 10:21 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Subject:** Invitation to join Scientific Advisory Board

Dear Dr. Fauci,

By way of this email, I would like to introduce our new biotech company based in California, Celestial Therapeutics Inc.

[REDACTED] (b) (4)



(b) (4)

We would like to extend an invitation to you to join our company's Scientific Advisory Board.

Please see attached herewith the executive summary and a slide deck of our company.

Thanks and looking forward to hearing from you shortly.

Best regards,

Ajay Gupta, Ph.D.  
President, Chairman & CEO  
Celestial Therapeutics Inc.

Tel: (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:07:36 +0000  
**To:** Billet, Courtney (NIH/NIAID) [E]  
**Subject:** FW: Lack of preparedness for the coronavirus pandemic

FYI. Does this deserve a response.

---

**From:** Nejat Duzgunes [REDACTED] (b) (6)  
**Sent:** Thursday, February 27, 2020 1:55 PM  
**To:** Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]  
[REDACTED] (b) (6)>  
**Cc:** Nejat Duzgunes [REDACTED] (b) (6)  
**Subject:** Lack of preparedness for the coronavirus pandemic  
**Importance:** High

Dear Dr. Collins and Dr. Fauci,

I am sorry to say that our lack of preparedness for the coronavirus pandemic has its roots in the way biomedical research is funded in the United States, as well as in the lack of leadership and vision on the part of NIH and its institutes since the SARS coronavirus outbreak in 2003. I try to expand on these problems in the article below. I would welcome your response to my thesis.

Sincerely,

Nejat Düzgüneş, Ph.D.  
Professor of Microbiology  
Department of Biomedical Sciences  
Arthur A. Dugoni School of Dentistry  
University of the Pacific  
155 Fifth Street, Room 412  
San Francisco, CA 94103

[REDACTED] (b) (6)



[The Wuhan Coronavirus \(COVID-19\): Why there is no cure or vaccine](#)

In their *Medical Virology* text published in 1994, D.O. White and F.J. Fenner stated “No convincing evidence has yet been obtained to link human coronaviruses with serious disease ..., but they are an important cause of that trivial but annoying disease, the common cold.” This generalization changed drastically with the emergence of the severe acute respiratory syndrome coronavirus in 2002-2003 (SARS-CoV), and the National Institutes of Health (NIH) immediately sought the expertise of these two scientists at the time. *Now, 17 years later, we still do not have an antiviral medicine or a vaccine against the novel coronavirus* that originated in China, now designated as COVID-19 by the World Health Organization (WHO). On February 21, there were 75,567 cases and 2,239 deaths in China; and 1,152 cases outside China, with 8 deaths, according to the Director-General of the WHO. The two viruses appear to use the same gate (or “receptor”) on host cells to infect them. Despite such expected similarities between new and old strains of the virus, research on coronaviruses has not been a priority for the National Institute of Allergy and Infectious Diseases (NIAID). In the end, all that the Director of NIAID was able offer is “good healthcare” as a remedy for COVID-19 infections.

*The major reason we do not have a cure for coronaviruses is that there has been no coordinated effort by the NIAID to establish long-term research programs focused on coronaviruses.* Realizing the insufficient progress in this area, the NIAID announced on February 6 a “Notice of Special Interest to highlight the urgent need for research on the 2019 novel Coronavirus.” Grants have indeed been awarded to some scientists since 2003, but such grants are highly competitive, with success rates of applications to NIAID between 14 and 18%, indicating that 82-86% of applicants are unable to obtain funding to carry out research. The *time* and *effort* spent on preparing grant applications to NIH are enormous, diverting these precious resources from actual research to what some scientists call “grantsmanship” (essentially, the ability to sell your idea to a review committee!). These “games scientist play” to procure funding are a hindrance to the progress of science. *The fact that we do not have a cure or a vaccine against coronaviruses over the past 17 years since the SARS epidemic, attests to this detrimental effect.*

*Development of a vaccine against COVID-19t is also not straightforward.* SARS was probably not considered by NIH to be an important pathogen on which to



spend resources. Even if the biomedical research community had developed a vaccine against coronaviruses, pharmaceutical companies would probably not have considered it a profitable endeavor. *Therefore, it is essential for public funds to be used by NIH and the CDC to both discover an effective vaccine and to manufacture it.*

We need to ensure that long-term projects to develop antivirals and vaccines against coronaviruses and other infectious agents, including tuberculosis and influenza virus, are implemented and fully funded. *We need to have a funding system that does not depend on the often unfounded criticism or whims of grant reviewers.* Although the current peer review system is touted generally as the best way to allocate funding, *it has never been tested scientifically* against an alternative. While half of the NIH budget (currently \$39 billion) may still be allocated for high-cost projects, including clinical trials, the other half should be awarded for periods of 10 years or longer to established scientists who have a track-record of scientific work, as well as to young scientists who are starting their first independent position. The budgets of these grants would be somewhat limited, but would provide uninterrupted funding and alleviate the stress of competing for renewals every 3–5 years. Scientists opting for these grants will not have to submit extensive grant applications. *More importantly, this system will more than double the number of independent investigators.* After a 10-12 year period, the scientific productivity (*per grant dollar*) of scientists on the classical grant system would be compared with that of scientists on long-term funding. *After all, the way we choose the mode of science funding should conform to the way science progresses, by experimentation and analysis.*



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:05:11 +0000  
**To:** Robert Durr  
**Subject:** RE: Covid-19

We will be looking at this.

**From:** Robert Durr [REDACTED] (b) (6)  
**Sent:** Thursday, February 27, 2020 2:03 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
**Subject:** Covid-19

Dr. Fauci,

This may be terribly simplistic, but if Covid-19 binds to ACE2 receptors in host cells, has anyone looked at ACE2 receptor blockers as potentially ameliorating disease severity or infectivity?

Sincerely,

Robert Alan Durr, M.D.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 04:04:26 +0000  
**To:** HMS-Faculty Affairs Senior Appointments  
**Subject:** RE: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD (b) (6)

Dear Dr. Cotti:

I am very sorry, but I just do not have time to do this right now. I am inundated 24/7 with coronavirus issues. I hope that you understand.

Best regards,

Tony

---

**From:** HMS-Faculty Affairs Senior Appointments  
<FacultyAffairs\_SeniorAppointments@hms.harvard.edu>  
**Sent:** Thursday, February 27, 2020 1:59 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Cotti, Dagmara <Dagmara\_Cotti@hms.harvard.edu>; Tekleab, Sarah <Sarah\_Tekleab@hms.harvard.edu>  
**Subject:** Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD – (b) (6)

Dear Dr. Fauci,

Harvard Medical School is currently considering (b) (6)

Attached is a letter from George Q. Daley, MD, PhD, Dean of the Faculty of Medicine at Harvard University and Caroline Shields Walker Professor of Medicine, requesting your evaluation of (b) (6) academic accomplishments. The following materials are also attached: (b) (6) curriculum vitae, an annotated bibliography of (b) (6) self-selected 10 most significant scholarly works, and the criteria by which (b) (6) qualifications are to be evaluated.

Please confirm receipt of this communication and let me know if you will be able to complete an evaluation. When composing your evaluation, please address the questions in Dean Daley's letter. We would greatly appreciate receiving letters of evaluation by **Thursday, March 26, 2020**. We are grateful for your time and expertise and we appreciate your consideration of this request.

Warm regards,  
Dagmara

**DAGMARA COTTI, PhD**

## **Program Director for Academic Affairs**

**Harvard Medical School | Office for Faculty Affairs**

Gordon Hall, 25 Shattuck Street, Suite 206 | Boston, MA 02115

**office:** 617.432.6889 | **fax:** 617.734.4382 | Hours: M-F 8:30am-4:00pm

[fa.hms.harvard.edu](http://fa.hms.harvard.edu)

**Executive Assistant: Sarah Tekleab**

[Sarah\\_Tekleab@hms.harvard.edu](mailto:Sarah_Tekleab@hms.harvard.edu) | **office:** 617.432.7438

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:57:45 +0000  
**To:** HJ Mai  
**Cc:** Billet, Courtney (NIH/NIAID) [E]  
**Subject:** RE: Confirmation of report

This is really not true. It was taken vey much out of context.

---

**From:** HJ Mai <HMai@npr.org>  
**Sent:** Thursday, February 27, 2020 2:09 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,  
HJ

 | HJ Mai | Editor, Morning Edition | [hmai@npr.org](mailto:hmai@npr.org) | (b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:54:23 +0000  
**To:** Billet, Courtney (NIH/NIAID) [E]  
**Subject:** FW: Idea for coronavirus contention

NIAID inquiries, Please

**From:** Blanco, Luz (NIH/NIAMS) [E] (b) (6) >  
**Sent:** Thursday, February 27, 2020 2:51 PM  
**To:** Collins, Francis (NIH/OD) [E] (b) (6) >  
**Cc:** Gottesman, Michael (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Idea for coronavirus contention  
**Importance:** High

Dears Dr Collins, Dr Gottesman, and Dr. Fauci:

I am reaching to you with this idea that might sound weird but I think it might be helpful. I have this idea to reduce the coronavirus infection and spreading. It is very simple but can get more complex as well.



(b) (5). I do not have the capacity to work or promote these ideas but hopefully you have the power for doing so. Thanks, regards

Luz P. Blanco PhD.  
Staff Scientist  
SAB, NIAMS, NIH

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:54:22 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Coronavirus : CONFIDENTIAL: (b) (4) info  
**Attachments:** image001.png, 2018\_Book\_UnderstandingTheHostImmuneResp.pdf, Advances in Clinical Chemistry 2018.pdf, BBASR-2016.pdf, Ch-22-francisandtaylor-2017.pdf, chapter-2012.pdf, GSH2005.pdf, HIVclinical trial2015.pdf, HIVclinical trial2017.pdf, macrophages2012.pdf, macrophages2013.pdf, NKCELLS2008.pdf, NKCELLS2012.pdf, RBC-HIV paper\_2014.pdf

Please take a look at this.

-----Original Message-----

**From:** Parikh, Purvi (b) (6)>  
**Sent:** Thursday, February 27, 2020 10:39 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Coronavirus : CONFIDENTIAL: (b) (4) info

Hi Dr Fauci

You must be swamped with coronavirus related correspondence but wanted to pass on some research that may prove helpful with coronavirus.

This pharmacist also plans to meet with Trump administration in upcoming weeks .

It may prove useful. I havent had a chance to dive deeply into the science of it so dont know efficacy but they are preparing a proof concept.

Main researcher is Nayan Patel and his email is (b) (6)

Sincererely,

Purvi Parikh, M.D., FACP  
Allergy/Immunology Attending Physician  
Clinical Assistant Professor, Department of Medicine and Department of Pediatrics Division of Infectious Diseases and Immunology Division of Rheumatology Allergy and Asthma Associates of Murray Hill  
212-685-4225 (office number)  
212-696-5682 (fax)

---

**From:** Purvi Parikh (b) (6)>  
**Sent:** Thursday, February 27, 2020 9:43:18 PM  
**To:** Parikh, Purvi  
**Subject:** Fwd: CONFIDENTIAL: (b) (4) info

[EXTERNAL]

Sent from my iPhone

Begin forwarded message:

From: Heather Pixton [REDACTED] (b) (6)>  
Date: February 3, 2020 at 12:43:59 PM EST  
To: [REDACTED] (b) (6)  
Subject: FW: Fwd: CONFIDENTIAL: [REDACTED] (b) (4) info

Hi Purvi,

Here is the email from Dr Patel with his research and other relevant PubMed links. The body of the email provides an idea of what he has been working on and how he hopes to contribute to the current outbreak.

I would be happy to connect Dr Patel with you (or someone you suggest) should you find the information provided warrants further inquiry.

Warm Regards,  
Heather

Heather Pixton  
CSO Pharmacology & Compliance | CABODI

[<https://res.cloudinary.com/drasifo1s/image/upload/v1544910436/1130-cedrec/cell.jpg>] <tel:+[REDACTED] (b) (6)>  
[REDACTED] (b) (6) I [<https://res.cloudinary.com/drasifo1s/image/upload/v1544910437/1130-cedrec/mail.jpg>]  
<mailto:Cedrec@SpectrumHP.com> Heather@CabodiCo.com<mailto:Heather@CabodiCo.com> I  
[<https://res.cloudinary.com/drasifo1s/image/upload/v1544910436/1130-cedrec/web.jpg>]  
<http://www.bestefekt.com><[https://urldefense.proofpoint.com/v2/url?u=http-3A\\_www.bestefekt.com\\_&d=DwMFaQ&c=j5oPpO0eBH1io48DtsedeElZfc04rx3ExJHeIIZuCs&r=TxekofMBvUAkTP9Z8swJDduMT3NwOKJuoZJ8jdtz5TG0&m=yoSwihtDq3ar56w9cqDSwhynOIH-OCP4NL4AZXwE63E&s=eCWhMiiUaJaCzK1mNZQpB21poltX9tSrIR2KsTm\\_Rol&e=>](https://urldefense.proofpoint.com/v2/url?u=http-3A_www.bestefekt.com_&d=DwMFaQ&c=j5oPpO0eBH1io48DtsedeElZfc04rx3ExJHeIIZuCs&r=TxekofMBvUAkTP9Z8swJDduMT3NwOKJuoZJ8jdtz5TG0&m=yoSwihtDq3ar56w9cqDSwhynOIH-OCP4NL4AZXwE63E&s=eCWhMiiUaJaCzK1mNZQpB21poltX9tSrIR2KsTm_Rol&e=>)>

[REDACTED] (b) (6)

From: Heather [REDACTED] (b) (6)>  
Sent: Monday, February 03, 2020 12:21 PM  
To: Heather Pixton [REDACTED] (b) (6)  
Subject: FW: Fwd: CONFIDENTIAL: [REDACTED] (b) (4) info

Sent from Mail<<https://go.microsoft.com/fwlink/?LinkId=550986>> for Windows 10

From: Cedrec Sumimoto<mailto:[REDACTED] (b) (6)>  
Sent: Saturday, February 1, 2020 12:30 PM  
To: Heather Pixton<mailto:[REDACTED] (b) (6)>  
Subject: Fwd: CONFIDENTIAL: [REDACTED] (b) (4) info

[REDACTED] (b) (6)

----- Forwarded Message -----  
Subject:

CONFIDENTIAL: [REDACTED] (b) (4) info

Date:

Fri, 31 Jan 2020 15:25:40 -0800

From:

Nayan Patel <[REDACTED]> (b) (6)

To:

Cedrec Sumimoto <[REDACTED]> (b) (6)

Hello Cedric,

[REDACTED] (b) (4)



(b) (4)

Best Wishes,

(b) (4)

CONFIDENTIALITY NOTICE: This e-mail message from Central Drugs (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review; use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message."



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:53:06 +0000  
**To:** Leonard Schleifer  
**Cc:** Erbeling, Emily (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: Regeneron COVID-19 update

Len:

Thanks for the note. Of course, we would be interested in working with you as you develop these antibodies.

Best regards,  
Tony

---

**From:** Leonard Schleifer [REDACTED] (b) (6)  
**Sent:** Thursday, February 27, 2020 3:25 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** Regeneron COVID-19 update

Tony,

Obviously you are swamped and the country is likely safer for it! I wanted to be sure you were up to date on our efforts re COVID-19. [REDACTED] (b) (4)

[REDACTED] (b) (4)

We have had discussions with our partners at BARDA and have had contact with the White House.

[REDACTED] (b) (4)

In the near future we will have a cocktail of antibodies ready for testing and we would be delighted to work with you and the NIH if that makes sense.

If you would like to discuss further, please call my cell [REDACTED] (b) (6) at anytime.

Len

\*\*\*\*\* This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron

Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.  
\*\*\*\*\*

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:42:11 +0000  
**To:** Phillips, Kyra  
**Subject:** RE: Confidential

Thanks, Kyra.

-----Original Message-----

From: Phillips, Kyra <Kyra.Phillips@abc.com>  
Sent: Thursday, February 27, 2020 4:33 PM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
Subject: Confidential

Dear Tony,

This note is between long time colleagues.

This entire Coronavirus story, and the handling of it, has really escalated into an unexpected journey. I want you to know how much I have respected you professionally and medically for nearly 20 years. I also want you to know that I have appreciated how we have communicated through the years about threats to our world's health and how honest and transparent you have always been. I know you are in a unique situation and I want you to know that I respect that and would never put you in a situation with my correspondence that would jeopardize you in anyway. With that said, I hope you can keep me informed, off the record if need be, so I can continue to cover this story honestly and fairly.

With utmost respect,

Kyra

@KyraPhillips  
ABC News  
Investigative Correspondent  
KyraPhillips.Com  
(b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:16:38 +0000  
**To:** Alice Park  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: Time follow up

Alice:

I am so sorry that I have not gotten back to you. I have been inundated 18 to 19 hours per day. By the time I get to e-mail it is late at night. I will try to connect with you tomorrow.

Best,

Tony

**From:** Alice Park <[alice.park@time.com](mailto:alice.park@time.com)>  
**Sent:** Thursday, February 27, 2020 5:17 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Re: Time follow up

Hi -- do you have a few minutes to talk about the following? Happy to chat whenever you're free. Best, Alice

On Wed, Feb 26, 2020 at 11:50 AM Alice Park <[alice.park@time.com](mailto:alice.park@time.com)> wrote:

Hi Dr. Fauci -- have a couple of requests for you, one of which is to speak at our upcoming Time 100 Summit in April -- about COVID-19. I'll be sending a formal invite but wanted to explore your interest and availability.

Also wanted to speak to you about a story I'm working on concerning the risk of community spread of COVID-19 in the US. Wanted to get your perspective on the CDC warning and where those cases might come from. Happy to chat whenever you're free; I'm relatively free today and this evening. Best, Alice

**PLEASE NOTE NEW PHONE NUMBER**

Alice Park

**TIME**

212 522 9830

[alice.park@time.com](mailto:alice.park@time.com)

@aliceparkny

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 02:49:34 +0000  
**To:** Suzanne Bradley  
**Subject:** RE: URGENT

There is much misinformation. I actually have not been muzzled at all by the Vice President. And BTW, it is safe to fly domestically (b) (6).

-----Original Message-----

**From:** Suzanne Bradley (b) (6)>  
**Sent:** Thursday, February 27, 2020 5:32 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Subject:** URGENT

Dear Dr. Fauci,

I understand Vice President Pence has ordered you to not inform the public about Coronavirus without approval. This is quite terrifying, especially since Trump has already shown his desire to spread false or incomplete information about this public health crisis.

I'm planning to fly domestically TOMORROW (b) (6). Is it safe??

Thank you,

Suzanne Bradley

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 02:46:07 +0000  
**To:** NIAID OD AM  
**Subject:** FW: question

Let us discuss, but almost certainly no.

**From:** Fleisher, Thomas (NIH/CC/DLM) [V] (b) (6) >  
**Sent:** Thursday, February 27, 2020 5:36 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Lang, David <LANGD@ccf.org>; Kay Whalen <KWhalen@aaaai.org>; Rebecca Brandt (AAAAI) <rbrandt@aaaai.org>  
**Subject:** question

Tony,

As you are acutely aware, the COVID-19 situation is on everyone's mind and accordingly there have been questions raised by members of the AAAAI about what the organization can do to provide more guidance in this evolving situation. In light of this linked to the fact that our annual meeting begins March 13 in Philadelphia, we have made the decision to have a 45-60 minute session in the main hall on Saturday (March 14) morning from 7:00-8:00 prior to the scheduled plenary session slated to start at 8:15. My question is whether you would consider taking the Acela up Friday evening returning Saturday morning to host this session with a presentation followed by a Q&A session. If that is not possible, would you be willing to provide a 10-15 minute (shorter if you deem that appropriate) video generated as close to the 14<sup>th</sup> as possible that we would have projected in the main hall as noted above. If the latter, would you have a suggestion of an ID person in Philadelphia who would be knowledgeable and could field questions following your video. I recognize that even if you are willing to come to Philadelphia, that circumstances could arise that would preclude your traveling in which case we would ask for a video if at all possible. Finally, if neither option is possible, is there somebody in DC (including NIH), Baltimore or Philadelphia who could provide the short review and then sit for 30-45 minutes of Q&A. I am well aware that this is last minute and you have been incredibly busy with issues related to the pandemic, any help you could provide would be much appreciated by my colleagues and me.

Regards,

Tom

Thomas A. Fleisher, M.D.  
Scientist Emeritus  
Department of Laboratory Medicine  
NIH Clinical Center  
Bethesda, MD 20892  
(b) (6) (tel)  
301-402-1612 (fax)

The contents of this message, together with any attachments, are intended only for the use of the person(s) to which they are addressed and may contain confidential and/or privileged information. Further, any medical information herein is confidential and protected by law. It is unlawful for unauthorized persons to

use, review, copy, disclose, or disseminate confidential medical information. If you are not the intended recipient, immediately advise the sender and delete this message and any attachments. Any distribution, or copying of this message, or any attachment, is prohibited.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 02:43:32 +0000  
**To:** NIAID OD AM  
**Subject:** FW: Invitation to speak at National Academies workshop  
**Attachments:** FMT Vaccines SOT 12.20.pdf

Let us discuss.

---

**From:** Pavlin, Julie <JPavlin@nas.edu>  
**Sent:** Thursday, February 27, 2020 6:04 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Subject:** Invitation to speak at National Academies workshop

Dear Dr. Fauci,

It is my pleasure to invite you to present at the National Academies of Sciences, Engineering, and Medicine workshop on "The Critical Public Health Value of Vaccines – Tackling Issues of Access and Hesitancy." This workshop will be held on May 28-29, 2020 at the Pan American Health Organization (PAHO) headquarters in Washington, DC. The statement of task for the workshop is attached.

The 1.5-day workshop will provide a venue to examine the current state of vaccine preventable diseases and the impact of vaccine access and hesitancy on vaccine preventable diseases globally, as well as the multidimensional drivers and impacts of declining vaccine confidence. This workshop will explore health systems, research opportunities, communication strategies, and policies that could be considered to address access, perceptions, attitudes, and behaviors toward vaccination. The workshop will be broadcast live over the web to an international audience, and is being hosted by the National Academies' Forum on Microbial Threats.

Due to your in-depth expertise in this field, we would like to invite you to give a plenary presentation on **the development of new vaccines in the midst of an outbreak, specifically on the prospects of a coronavirus vaccine**. The primary audience for the event will be researchers, health practitioners, industry leaders, and policy makers in infectious diseases and global health, so we are looking to initiate this workshop with relevant discussions of barriers to accessing vaccines. Your responsibilities would be to prepare and deliver a 15-minute presentation. We would cover your travel expenses in accordance with U.S. federal government rules. We would be thankful to have your involvement in this workshop. Please let me know if you might be interested. I would be happy to answer any questions you may have.

Thank you in advance for your time and consideration. We understand that this is a very busy time and your calendar may be in flux.

Best wishes,

Julie

**Julie A. Pavlin, MD, PhD, MPH**

Director, Board on Global Health

Health and Medicine Division – Find us at [nationalacademies.org/HMD](https://nationalacademies.org/HMD)

The National Academies of Sciences, Engineering, and Medicine

500 Fifth Street, NW  
Washington, DC 20001  
Phone: 202-334-2171

Follow Us   

---

*The National Academies of*  
**SCIENCES • ENGINEERING • MEDICINE**

---

=====

ORGANIZING COMMITTEE – THE CRITICAL PUBLIC HEALTH VALUE OF VACCINES – TACKLING ISSUES OF ACCESS AND HESITANCY

**HEIDI LARSON** (Co-Chair), Professor of Anthropology, Risk and Decision Science, London School of Hygiene & Tropical Medicine

**MATTHEW ZAHN** (Co-Chair), Medical Director, Division of Epidemiology and Assessment, Orange County Health Care Agency

**KEVIN ANDERSON**, Senior Program Manager, Chemical & Biological Defense Division, Science & Technology Directorate, Department of Homeland Security

**ALISON BUTTENHEIM**, Associate Professor, Family and Community Health, School of Nursing, University of Pennsylvania

**ANDREW CLEMENTS**, Deputy Director, Pandemic Influenza and Other Emerging Threats Unit, USAID

**AMANDA COHN**, Executive Secretariat, Advisory Committee on Immunization Practices, US Centers for Disease Control and Prevention

**PETER DASZAK**, President, EcoHealth Alliance

**EVA HARRIS**, Professor and Director, Division of Infectious Diseases and Vaccinology, Center for Global Public Health, University of California, Berkeley

**ELIZABETH D. HERMSEN**, Head, Global Antimicrobial Stewardship, Merck & Co., Inc.

**NONI MACDONALD**, Professor, Department of Pediatrics, Dalhousie University, Nova Scotia, Canada

**WALT ORENSTEIN**, Professor and Associate Director, Emory Vaccine Center

=====

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 02:42:42 +0000  
**To:** Jon Cohen  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: Interview request--typo fixed

Jon:

I am drowning right now. However, I am always happy to speak with you. Cannot do it until I dig out from under. Hopefully, soon.

Best,  
Tony

-----Original Message-----

From: Jon Cohen <jcohen@aaas.org>  
Sent: Thursday, February 27, 2020 5:48 PM  
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
Subject: Interview request--typo fixed

Dr. Fauci,

I was most pleased to hear Sec. Azar's commitment to "radical transparency." In that vein, I would like to interview you about COVID-19 for a Science magazine article I am preparing.

Thanks in advance,

Jon Cohen  
Science



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 02:32:50 +0000  
**To:** Billet, Courtney (NIH/NIAID) [E]  
**Cc:** Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

That is not what I said. I said for SARS the virus went from bat to civet cat to human; for MERS it went from bat to camel to human. I said we did not know what the animal reservoir was for the jump from animal to human with the novel coronavirus. Please tell her that. Thanks.

---

**From:** Billet, Courtney (NIH/NIAID) [E] (b) (6)  
**Sent:** Thursday, February 27, 2020 7:12 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Folkers, Greg (NIH/NIAID) [E] (b) (6) Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Subject:** Fwd: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Q from Donna Young re comments In VP pool report:

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?  
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

---

**From:** "Young, Donna" <[Donna.Young@spglobal.com](mailto:Donna.Young@spglobal.com)>  
**Date:** Thursday, February 27, 2020 at 7:01:00 PM  
**To:** "Billet, Courtney (NIH/NIAID) [E]" <(b) (6)>  
**Cc:** "Stover, Kathy (NIH/NIAID) [E]" (b) (6) >, "NIAID NEWS (NIH/NIAID)" <[NIAIDNEWS@niaid.nih.gov](mailto:NIAIDNEWS@niaid.nih.gov)>, "Myles, Renate (NIH/OD) [E]" (b) (6)  
**Subject:** Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Also, can you please clarify what was in the VP pool report today.

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?  
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

Thank you again.



Donna Young  
Senior Reporter, Healthcare (Washington, DC)  
S&P Global News  
[donna.young@spglobal.com](mailto:donna.young@spglobal.com)

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

---

**From:** Billet, Courtney (NIH/NIAID) [E] (b) (6)>  
**Sent:** Thursday, February 27, 2020 6:55 PM  
**To:** Young, Donna <[Donna.Young@spglobal.com](mailto:Donna.Young@spglobal.com)>  
**Cc:** Stover, Kathy (NIH/NIAID) [E] (b) (6)>; NIAID NEWS (NIH/NIAID) <[NIAIDNEWS@niaid.nih.gov](mailto:NIAIDNEWS@niaid.nih.gov)>; Myles, Renate (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>  
**Subject:** Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Can you just attribute to NIAID spox? I ask because he's on meetings and calls...,,

---

**From:** "Young, Donna" <[Donna.Young@spglobal.com](mailto:Donna.Young@spglobal.com)>  
**Date:** Thursday, February 27, 2020 at 6:52:48 PM  
**To:** "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>  
**Cc:** "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "NIAID NEWS (NIH/NIAID)" <[NIAIDNEWS@niaid.nih.gov](mailto:NIAIDNEWS@niaid.nih.gov)>, "Myles, Renate (NIH/OD) [E]" (b) (6)>  
**Subject:** Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Is Dr. Fauci stating it is not true? Do I attribute to him or you stating the New York Times report is not true?

Thank you for your help.

Donna Young  
Senior Reporter, Healthcare (Washington, DC)  
S&P Global News  
[donna.young@spglobal.com](mailto:donna.young@spglobal.com)

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

---

**From:** Billet, Courtney (NIH/NIAID) [E] (b) (6)  
**Sent:** Thursday, February 27, 2020 6:39 PM  
**To:** Young, Donna <[Donna.Young@spglobal.com](mailto:Donna.Young@spglobal.com)>  
**Cc:** Stover, Kathy (NIH/NIAID) [E] (b) (6); NIAID NEWS (NIH/NIAID) <[NIAIDNEWS@niaid.nih.gov](mailto:NIAIDNEWS@niaid.nih.gov)>; Myles, Renate (NIH/OD) [E] (b) (6)  
**Subject:** Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Donna, so sorry, it's been a crazy day. We are not sure exactly where this came from. It's not true.

---

**From:** "Young, Donna" <[Donna.Young@spglobal.com](mailto:Donna.Young@spglobal.com)>  
**Date:** Thursday, February 27, 2020 at 5:32:22 PM  
**To:** "NIAID NEWS (NIH/NIAID)" (b) (6), "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "Myles, Renate (NIH/OD) [E]" (b) (6), "Billet, Courtney (NIH/NIAID) [E]" (b) (6)  
**Subject:** Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Hi. I'm still waiting for a response on this. Could you at least tell me me you are going to respond?

Thank you.

Donna Young  
Senior Reporter, Healthcare (Washington, DC)  
S&P Global News  
[donna.young@spglobal.com](mailto:donna.young@spglobal.com)

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

---

**From:** Young, Donna

**Sent:** Thursday, February 27, 2020 1:35 PM

**To:** NIAID NEWS (NIH/NIAID) <[NIAIDNEWS@niaid.nih.gov](mailto:NIAIDNEWS@niaid.nih.gov)>; Stover, Kathy (NIH/NIAID) [E]

(b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)>

**Subject:** Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Good Day: Could you please comment on this report from the New York Times that Dr. Fauci has been told that he must clear anything he plans to say about the coronavirus outbreak with the White House before he speaks to any media?

<https://www.nytimes.com/2020/02/27/us/politics/us-coronavirus-pence.html>

"Dr. Anthony S. Fauci, one of the country's leading experts on viruses and the director of the National Institute of Allergy and Infections Diseases, told associates that the White House had instructed him not to say anything else without clearance."

Has Dr. Fauci or any other NIH official been told by the White House they cannot speak to the media unless cleared by the White House?

Please do let me know.

Thank you for your help.

Donna Young  
Senior Reporter, Healthcare (Washington, DC)  
S&P Global News  
[donna.young@spglobal.com](mailto:donna.young@spglobal.com)

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

The information contained in this message is intended only for the recipient, and may be a confidential attorney-client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. S&P Global Inc. reserves the right, subject to applicable local law, to monitor, review and process the content of any electronic message or information sent to or from S&P Global Inc. e-mail addresses without informing the sender or recipient of the message. By sending electronic message or information to S&P Global Inc. e-mail addresses you, as the sender, are consenting to S&P Global Inc. processing any of your personal data therein.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 00:47:19 +0000  
**To:** Mark Zuckerberg  
**Subject:** RE:

Mark:

Thanks for the note. If we start in April ( ~6-7 weeks from now) with a phase 1 trial of 45 subjects, it will take another 3-4 months to determine safety and some immunogenicity. The next step is phase 2 for efficacy. We may need help with resources for the phase 2 trial if we do not get our requested budget supplement. I believe that we will be OK. If this goes off track, I will contact you. Many thanks for the offer. Much appreciated.

Best regards,

Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX: (301) 496-4409**  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Mark Zuckerberg (b) (6)  
**Sent:** Thursday, February 27, 2020 7:16 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Subject:**

Tony:

I was glad to hear your statement that the covid-19 vaccine will be ready for human trials in six weeks. Are there any resources our foundation can help provide to potentially accelerate this or at least make sure it stays on track?

Mark

**From:** (b) (6)  
**Sent:** Thu, 27 Feb 2020 17:43:18 -0500  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Fwd: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Sent from my iPhone

Begin forwarded message:

**From:** Kristen Fischer <(b) (6)>  
**Date:** February 27, 2020 at 5:20:21 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >  
**Subject:** Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Hi there,

I'm writing for Healthline about coronavirus and how the virus spread may be different in the Southern Hemisphere (they mention that in the story below). Care to weigh in?

I'd love to know:

1. Will coronavirus be any less severe in the Southern Hemisphere due to the summer weather there at the moment?
2. Will the virus spread in North America slow down due to geography or warmer weather at all? What can we expect in 3 months--and in one year as far as coronavirus in the U.S.?
3. Will it differ in how it spreads/tapers off in Asia, due to proximity of the outbreak?
4. Will this eventually be gone or will it be something that is a new health threat that could return in a year or so?
5. Any insight into the outlook of coronavirus, how it will spread or how long it will be active?

Looking for a brief email response by Monday morning at 10 a.m. Let me know if you can assist!

Warmly,  
Kristen Fischer

--  
Kristen Fischer  
[www.kristenfischer.com](http://www.kristenfischer.com)  
(b) (6)

Find your family fun at the Jersey Shore--get your [free weekly e-newsletter](#) today!  
See your product or service [Re-viewed by Kristen Fischer](#)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 27 Feb 2020 16:29:44 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Covid-19--Conference Call Invitation

Let us discuss. Likely do not have time for this.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Buono, Lucia <LBUONO@imf.org> **On Behalf Of** Gopinath, Gita  
**Sent:** Wednesday, February 26, 2020 2:22 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Gopinath, Gita <GGopinath@imf.org>; Milesi-Ferretti, Gian Maria <GMILESIFERRETTI@imf.org>; Celasun, Oya <OCelasun@imf.org>; Nabar, Malhar Shyam <MNabar@imf.org>; Christiansen, Lone Engbo <LChristiansen@imf.org>; Buono, Lucia <LBUONO@imf.org>  
**Subject:** Covid-19--Conference Call Invitation

**On behalf of Ms. Gopinath:**

Dear Professor Fauci:

We are contacting you in the context of the evolving spread of Covid-19, which is already impacting livelihoods and economic activity in several countries. As you may know, the IMF publishes forecasts of economic growth for member countries four times a year, as well as macroeconomic policy recommendations. In that context, it would be invaluable for us to hear public health experts' views on the likely trajectory of the virus—the number of people that are likely to get infected in different countries and the likely time path. We would also benefit from hearing experts' views on the optimal public health policy response in different types of countries (countries with stronger or weaker health systems, different development levels, etc.), and the implied resource needs.

We are planning to set up a conference call with several experts to discuss these issues and were wondering if you would be available to join us. If you would be interested in joining, would you be able

to let my assistant Lucia Buono ([lbuono@imf.org](mailto:lbuono@imf.org)) know of some dates and times that would work for you this week or early next week?

We would be extremely grateful for any guidance you might be able to offer as we strive to do our part in helping member countries respond to the epidemic.

Best regards,

Gita Gopinath  
Economic Counsellor and Director  
Research Department  
International Monetary Fund



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 27 Feb 2020 13:31:19 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** FW: The global health leaders call, Wednesday 4 March at 13:00 CET  
**Attachments:** (b) (4) Swisscom Call code.pdf

FYI

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** RYAN, Michael J. (b) (6) >  
**Sent:** Thursday, February 27, 2020 7:55 AM  
**To:** Redfield, Robert R. (CDC/OD) (b) (6)  
(b) (6)  
(b) (6) Felicity Harvey  
(b) (6) Chris.Elias  
(b) (6); Jeremy Farrar  
(b) (6); Fauci, Anthony  
(NIH/NIAID) [E] (b) (6)  
(b) (6) Conrad, Patricia (NIH/NIAID) [E]  
(b) (6); Thomas R. Frieden (b) (6)  
(b) (6) Lynn Banks (b) (6); President | Resolve to Save Lives  
<president@resolvetosavelives.org>; (b) (6)  
(b) (6)  
(b) (6)  
Tarik Mohammed (b) (6) >  
**Cc:** SHOC <shoc@who.int>; Office of the Director-General <DGOoffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6) >; MAHJOUR, Jaouad (b) (6) >; FALL, Ibrahima Soce (b) (6) >; GREIN, Thomas (b) (6) >; MINHAS, Raman (b) (6) >; COX, Paul Michael (b) (6) >; AL-SHORBAJI, Farah (b) (6) >; POOLE, Marcia (b) (6) >; DRURY, Patrick Anthony (b) (6) >; GRAAFF, Peter Jan <(b) (6) >; Dr VAN KERKHOVE, Maria (b) (6) >; KABIR, Sophia

(b) (6); FARES, Christine Youssef (b) (6)

**Subject:** The global health leaders call, Wednesday 4 March at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on Wednesday, 4 March at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6); mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 27 Feb 2020 04:44:07 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: [EXTERNAL] RE: Hardball Tonight

FYI. (b) (6).

-----Original Message-----

From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>  
Sent: Wednesday, February 26, 2020 2:39 PM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
Subject: Re: [EXTERNAL] RE: Hardball Tonight

When you can and are ready, I would love to have you on Hardball anytime in the 7pm hour tonight, tomorrow or Friday.

Sent from my iPhone

> On Feb 26, 2020, at 11:34 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

>

> Chris:

> I am always happy to be on your show. I am hearing that they want us to hold on doing any interviews for the time being since the POTUS might do a press conference tonight. And so the decision is still in flux.

> Tony

>

> Anthony S. Fauci, MD

> Director

> National Institute of Allergy and Infectious Diseases Building 31,

> Room 7A-03

> 31 Center Drive, MSC 2520

> National Institutes of Health

> Bethesda, MD 20892-2520

> Phone (b) (6)

> FAX: (301) 496-4409

> E-mail: (b) (6)

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

>

> -----Original Message-----

> From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>

> Sent: Wednesday, February 26, 2020 9:04 AM

> To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

> Subject: Hardball Tonight

>

> Dear Tony -

>

> Could you come on tonight to address the coronavirus? We'd like to

> have you on anytime in the 7 hour. (b) (6)

>

> Best, Chris

>  
> Sent from my iPhone



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 27 Feb 2020 04:35:33 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Can you chat?

Please set this up. Thanks.

---

**From:** Fox, Lauren <Lauren.Fox@turner.com>  
**Sent:** Wednesday, February 26, 2020 5:41 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Can you chat?

Hey Dr. Fauci,

I wanted to reach out because I am working on a big piece about the effort behind the scenes to contain the coronavirus and I was hoping you could talk on background about that,

Best,

Lauren Fox

Lauren Fox  
Congressional Reporter  
**CNN Politics**  
[Lauren.Fox@turner.com](mailto:Lauren.Fox@turner.com)  
(b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 27 Feb 2020 04:34:46 +0000  
**To:** Arturo Casadevall  
**Subject:** RE: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Arturo:

Thank you for your note and for sending the OpEd. Nice Job! I hope that all is well with you.

Best,

Tony

---

**From:** Arturo Casadevall <(b) (6)>  
**Sent:** Wednesday, February 26, 2020 5:45 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
**Subject:** My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Dear Tony,

I just had an OpEd accepted in the WSJ proposing the use of convalescent sera to stem the coronavirus epidemic. The text of the OpEd is below in blue font (scroll down). I am sure the WSJ will shorten it and edit it but at least you have an advance copy of it. I just wanted you to have it since the WSJ is read widely in DC and I don't want anyone blindsiding you with questions about it.

As you know I have been long proponent of passive antibody therapies in infectious diseases and there is a huge body of historical data supporting this approach. Certainly, with modern blood banking techniques this option can be made quite safe and administration of a few cc's of serum could confer immediate immunity to those who will be exposed – like ER staff. I hope you agree with the message and like it.

Thank you for all you are doing for the country and humanity. If you need me for anything in this crisis rest assured that I am here.

Warm regards,  
Arturo

**From:** Taranto, James <[james.taranto@wsj.com](mailto:james.taranto@wsj.com)>  
**Sent:** Wednesday, February 26, 2020 4:27 PM  
**To:** Arturo Casadevall <(b) (6)>  
**Subject:** Re: Asking for a quick decision on the submitted OpEd on stemming coronavirus epidemic

OK, we'll take this and aim to get it out in Friday's paper, though it will likely need some trimming for space.

Dear Mr. Varadarajan,

I wonder if the WSJ is interested in my OpEd. I am trying to get a message out that convalescent serum (e.g. serum from people who recover) can be used to stem the coronavirus epidemic if administered to exposed people. This has been known for over a century, and is well accepted, but not widely known, even among experts today. There was one report that China was beginning to stockpile serum but there has been almost no discussion of this option among world public health authorities. Although I can get this published in a medical journal my hope is to publish it instead in a venue of high readership since this is something that can be done today to stem the epidemic. I am hoping that given the economic consequences of the outbreak that the WSJ is interested. I included a brief bio below. Thanks for looking at this.  
Arturo

Proposed op-ed.

**To Stem the Coronavirus Epidemic use Survivors Blood.**

(b) (4)

Arturo Casadevall MD, PhD

**Author's brief bio**

Arturo Casadevall, M.D., Ph.D., is a Bloomberg Distinguished Professor and Chair of the Molecular Microbiology and Immunology at Johns Hopkins School of Public Health. He received his M.D. and Ph.D. degrees from New York University. He completed his internship/residency in internal medicine at Bellevue Hospital and specialized in Infectious Diseases at the Albert Einstein College of Medicine. The author of over 800 papers, books and chapters, his major research interests are in fungal pathogenesis and the mechanisms of antibody action. He is also interested in the problems with scientific enterprise and with collaborators showed that misconduct accounts for the majority of retracted publications. He is editor-in-chief of mBio, Deputy Editor of the Journal of Clinical Investigation and serves on several editorial boards. He has served on several NIH committees including the NIAID Strategic Plan, the Blue Ribbon Panel on Biodefense Research, the NAS panel that reviewed the FBI investigation on anthrax attacks, the NAS Federal Regulations and Reporting committee and the National Science Advisory Board for Biosecurity. He was a Commissioner



in the National Commission on Forensic Science and previously served as President of the Medical Mycology Society of the Americas. He is currently the Chair the Board of Governors of the American Academy of Microbiology. He has received numerous honors including election to the American Society for Clinical Investigation, American Academy of Physicians, American Academy of Microbiology, Fellow of the American Academy for the Advancement of Science, American Academy of Arts and Sciences and the National Academy of Medicine.

Arturo Casadevall MD, PhD  
Chair, Molecular Microbiology & Immunology  
Alfred & Jill Sommer Professor and Chair  
Bloomberg Distinguished Professor  
Johns Hopkins School of Public Health  
615 N. Wolfe Street  
Room E5132  
Baltimore, Maryland 21205

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 6 Mar 2020 03:48:12 +0000  
**To:** Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]  
**Subject:** RE: For Review: [REDACTED] (b) (5)

Thanks.

---

**From:** Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Sent:** Thursday, March 5, 2020 10:15 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** FW: For Review: [REDACTED] (b) (5)

**Importance:** High

---

**From:** "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>  
**Date:** Thursday, March 5, 2020 at 6:19 PM  
**To:** "Stannard, Paula (HHS/IOS)" [REDACTED] (b) (6) "Agnew, Ann (HHS/IOS)" [REDACTED] (b) (6)>, "Trueman, Laura (HHS/IEA)" [REDACTED] (b) (6) "Kadlec, Robert (OS/ASPR/IO)" [REDACTED] (b) (6)>, "Bird, Catherine (OS/OGC)" <[REDACTED] (b) (6)>, "Hittle, Taylor (HHS/ASFR)" <[REDACTED] (b) (6)>, "Arbes, Sarah (HHS/ASL)" [REDACTED] (b) (6)>, "Murphy, Ryan (OS/ASPA)" [REDACTED] (b) (6)>, "Destro, Brenda (HHS/ASPE)" [REDACTED] (b) (6)>, "Nevel, Amy (HHS/ASPE)" [REDACTED] (b) (6)>, "Tobias, Constance (HHS/DAB)" <[REDACTED] (b) (6)>, "Giroir, Brett (HHS/OASH)" [REDACTED] (b) (6)>, "Schwartz, Erica (HHS/OASH)" <[REDACTED] (b) (6)>, "Severino, Roger (HHS/OCR)" <[REDACTED] (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" <[REDACTED] (b) (6)>, "Kerr, Lawrence (HHS/OS/OGA)" [REDACTED] (b) (6)>, "Chang, William (HHS/OGC)" [REDACTED] (b) (6)>, "Taitzman, Julie K (OIG/IO)" [REDACTED] (b) (6)>, "Griswold, Nancy (HHS/OMHA HQ)" [REDACTED] (b) (6)>, "Rucker, Donald (OS/ONC)" <[REDACTED] (b) (6)>, "Johnson, Lynn (ACF)" [REDACTED] (b) (6)>, "Meyers, David (AHRQ/IOD)" [REDACTED] (b) (6) "McNellis, Robert (AHRQ/CEPI)" [REDACTED] (b) (6)>, "Patel, Anita (CDC/DDID/NCIRD/OD)" [REDACTED] (b) (6), "Ethier, Kathleen (CDC/DDID/NCHHSTP/DASH)" <[REDACTED] (b) (6)>, "Brookes, Brady (CMS/OA)" [REDACTED] (b) (6) "Hinton, Denise (FDA/OC)" [REDACTED] (b) (6)>, "Cheever, Laura (HRSA)" [REDACTED] (b) (6),

"Espinosa, Diana (HRSA)" (b) (6) >, "Macrae, Jim (HRSA)" (b) (6) >,  
"Weahkee, Michael (IHS/HQ)" < (b) (6) >, "McCollum, Jeffrey T (IHS/HQ)"  
(b) (6) >, "Frazier, Francis (IHS/HQ)" < (b) (6) >, "Collins,  
Francis (NIH/OD) [E]" (b) (6) >, Anthony Fauci < (b) (6) >, Hilary  
Marston (b) (6) >, "McCance-Katz, Elinore (SAMHSA/OAS)"  
(b) (6) >, "Shuy, Bryan (OS/ASPR/IO)" < (b) (6) >,  
"Yeskey, Kevin (OS/ASPR/IO)" (b) (6) >, Rick Bright (b) (6) >,  
"Disbrow, Gary (OS/ASPR/BARDA)" (b) (6) >, "Phillips, Sally (OS/ASPR/SPPR)"  
< (b) (6) >, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6) >,  
"DeBord, Kristin (OS/ASPR/SPPR)" (b) (6) >, "Vineyard, Michael  
(OS/ASPR/IO)" (b) (6) >, "Dodgen, Daniel (OS/ASPR/SPPR)"  
(b) (6) >, "Imbriale, Samuel (OS/ASPR/SIIM)" < (b) (6) >,  
"Donnelly, Kelsey (OS/ASPR/SPPR) (CTR)" (b) (6) >, "Haris, Mariam  
(OS/ASPR/SPPR) (CTR)" (b) (6) >, "Fucci, Michael (OS/ASPR/SPPR) (CTR)"  
(b) (6) >, "Roman-Stolte, Claudia (OS/ASPR/SPPR) (CTR)" (b) (6) >,  
(b) (6) >, "Austin, Meredith (uscg.mil)" (b) (6) >, "Perdue,  
Christopher (OS/ASPR/SPPR)" (b) (6) >, "Herrmann, Jack  
(OS/ASPR/OEA)" (b) (6) >, Robert Johnson (b) (6) >,  
"Wong, Diana (OS/ASPR/SIIM)" (b) (6) >, "Robertson, Lance (ACL)"  
(b) (6) >, "Nicholls, Richard (ACL)" < (b) (6) >,  
"Phillips, Christine (ACL)" (b) (6) >, "Blatner, Gretta (OS/ASPR/BARDA)"  
(b) (6) >, "Feeney, Kathryn (OS/ASPR/IO) (CTR)" < (b) (6) >,  
"Shirley, Mayo (FDA/OC)" (b) (6) >, "Sheehy, Janice (FDA/ORA)"  
(b) (6) >, "McDaniel, Eileen (HHS/OMHA)" < (b) (6) >,  
Linda Lambert (b) (6) >, "Gin, Julia (OS/ASPR/SPPR)" (b) (6) >,  
"Adams, Steven A. (CDC/SNS/DSNS)" (b) (6) >, "Wolf, Laura (OS/ASPR/SIIM)"  
(b) (6) >, "Lee, Scott (OS/ASPR/EMMO)" (b) (6) >, "Cooper, Kevin  
(OS/ASPR/ORM)" (b) (6) >, "Moudy, Robin (OS/ASPR/SPPR)"  
(b) (6) >, "Lawrence, Theresa (OS/ASPR/SPPR)"  
< (b) (6) >, "Baker, Michael (OS/IEA)" < (b) (6) >  
**Cc:** "Holland, Tara (OS/ASPR/EMMO)" (b) (6) >, "Delvecchio, Paolo  
(SAMHSA/OMTO)" (b) (6) >, "Lobos, Elisa (SAMHSA/OFR/OD)"  
(b) (6) >, "Bell, March (HHS/OCR)" (b) (6) >, "Frohboese,  
Robinsue (HHS/OCR)" < (b) (6) >, "Knutson, Donna  
(CDC/DDNID/NCEH/OD)" (b) (6) >, "Mackay, Thomas (OS/ASPR/EEAA)"  
(b) (6) >, "Mango, Paul (HHS/IOS)" (b) (6) >, "Blackford,  
Carol W. (CMS/CM)" (b) (6) >, "Bradsher, Kris (HHS/ASL)"  
(b) (6) >, "Payne, Skip (CMS/OA)" (b) (6) >, "Gettinger,  
Andrew (OS/ONC)" (b) (6) >, "Abbey, Rachel (OS/OSCP)"  
(b) (6) >, "Cosgrove, Sandra (OS/ASPR/EEAA)" < (b) (6) >,  
"Chaput, Daniel (OS/ONC)" (b) (6) >

**Subject:** For Review: (b) (5)



Dear Disaster Leadership Group (DLG) Members,

Attached for review is a draft paper [REDACTED] (b) (5)  
[REDACTED] We are asking that you review this draft and provide feedback to us by **8:00am on Friday, March 6**. Please note that we are looking for **substantive feedback only**.

If you have any questions or concerns, please reach out to me at [REDACTED] (b) (6) and kindly copy the [DLGDESK@hhs.gov](mailto:DLGDESK@hhs.gov).

Thank you,

**Daniel Dodgen, Ph.D.**

Senior Advisor

Office of the Assistant Secretary for Preparedness and Response (ASPR)

Office of Strategy, Policy, Planning and Requirements (SPPR)

---

**HEALTH AND HUMAN SERVICES (DHHS)** | O'Neill House Office Building | 200 C Street SW | Washington, DC 20515

o. [REDACTED] (b) (6)

[REDACTED] (b) (6) | [www.phe.gov](http://www.phe.gov)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Tue, 3 Mar 2020 11:12:55 +0000  
**To:** (b) (6) (OS/IOS)  
**Subject:** RE: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Oh, I see what they are getting at. They examined at the single cell level the expression of RNA for ACH2, which is the receptor for the Coronavirus in the lung, and found that when they looked at various demographic groups there was greater expression of this receptor in Asian males. They are thus hinting that this is the reason why there was such an explosion of infections in China. This is possible, but the lowest level was in Northern Italians and take a look at what is happening in Northern Italy. I do not mean to put the paper down since there may be some truth in it. However, this journal (bioRxiv) is not peer reviewed and the data are skimpy. Someone should do a more scholarly study.

-----Original Message-----

**From:** (b) (6) (OS/IOS) <(b) (6)>  
**Sent:** Tuesday, March 3, 2020 5:54 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
**Subject:** Re: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

They asked if this proved certain ethnic groups more likely to get the disease and I said I had never anything like that suggested to me by our leading scientists.

> On Mar 2, 2020, at 10:44 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:  
>

I do not know what question they asked you about this paper, but any question about this gene expression paper to a non-scientist would be unfair and inappropriate.

-----Original Message-----

**From:** (b) (6) (OS/IOS) <(b) (6)>  
**Sent:** Monday, March 2, 2020 9:55 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>  
**Cc:** Harrison, Brian (HHS/IOS) <(b) (6)>  
**Subject:** Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Was asked about this on tv tonight.

<https://www.biorxiv.org/content/10.1101/2020.01.26.919985v1>

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Tue, 3 Mar 2020 03:26:29 +0000  
**To:** Collins, Francis (NIH/OD) [E]; Giroir, Brett (HHS/OASH)  
**Cc:** Steele, Danielle (HHS/IOS); Tabak, Lawrence (NIH/OD) [E]  
**Subject:** RE: SARS CoV-2 in humanized mice

Ditto.

---

**From:** Collins, Francis (NIH/OD) [E] (b) (6)  
**Sent:** Monday, March 2, 2020 9:32 PM  
**To:** Giroir, Brett (HHS/OASH) (b) (6) >  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >; Steele, Danielle (HHS/IOS) (b) (6); Tabak, Lawrence (NIH/OD) [E] < (b) (6) >  
**Subject:** RE: SARS CoV-2 in humanized mice

Larry has it right. Tony may want to add.

Francis

---

**From:** Tabak, Lawrence (NIH/OD) [E] (b) (6)  
**Sent:** Monday, March 2, 2020 8:14 PM  
**To:** Giroir, Brett (HHS/OASH) (b) (6) >  
**Cc:** Collins, Francis (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Steele, Danielle (HHS/IOS) (b) (6)  
**Subject:** Re: SARS CoV-2 in humanized mice

Brett,

Tony or Francis may offer additional insight, but the (b) (5)

I hope this helps.

Larry

---

**From:** "Giroir, Brett (HHS/OASH)" < (b) (6) >  
**Date:** Monday, March 2, 2020 at 7:25 PM  
**To:** "Tabak, Lawrence (NIH/OD) [E]" (b) (6) >  
**Cc:** Francis Collins (b) (6) >, Anthony Fauci (b) (6) >, "Steele, Danielle (HHS/IOS)" (b) (6) >, "Giroir, Brett (HHS/OASH)" (b) (6)  
**Subject:** RE: SARS CoV-2 in humanized mice

Dear Larry,

Thank you for your patience. The question has been raised, (b) (5)

I appreciate your willingness to continue to work on this and respond to the questions that I am receiving.

V/r  
Brett

**Brett P. Giroir, MD**

ADM, US Public Health Service  
Assistant Secretary for Health (ASH)  
200 Independence Avenue, SW  
Washington, DC 20201  
Office Phone: (b) (6)

---

**From:** Tabak, Lawrence (NIH/OD) [E] (b) (6)  
**Sent:** Thursday, February 20, 2020 5:29 PM  
**To:** Giroir, Brett (HHS/OASH) (b) (6)>  
**Cc:** Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Steele, Danielle (HHS/IOS) (b) (6)>  
**Subject:** Re: SARS CoV-2 in humanized mice

Brett,  
I have discussed with both Francis and Tony (b) (5)

With regard to your questions:

(b) (5)

(b) (5)

Hope this is helpful. Please let me know if you require additional information.  
Best wishes,  
Larry

---

**From:** "Giroir, Brett (HHS/OASH)" <[REDACTED]> (b) (6)>  
**Date:** Thursday, February 20, 2020 at 12:32 PM  
**To:** "Tabak, Lawrence (NIH/OD) [E]" <[REDACTED]> (b) (6)  
**Cc:** "Steele, Danielle (HHS/IOS)" <[REDACTED]> (b) (6)  
**Subject:** RE: SARS CoV-2 in humanized mice

Can you give me a quick call?

(b) (5)

**Brett P. Giroir, MD**  
ADM, US Public Health Service  
Assistant Secretary for Health (ASH)  
200 Independence Avenue, SW  
Washington, DC 20201  
Office Phone: [REDACTED] (b) (6)

---

**From:** Tabak, Lawrence (NIH/OD) [E] <[REDACTED]> (b) (6)  
**Sent:** Thursday, February 20, 2020 12:19 PM  
**To:** Giroir, Brett (HHS/OASH) <[REDACTED]> (b) (6)>  
**Cc:** Steele, Danielle (HHS/IOS) <[REDACTED]> (b) (6)>  
**Subject:** Re: SARS CoV-2 in humanized mice



(b) (5)

Thanks

Larry

---

**From:** "Giroir, Brett (HHS/OASH)" [REDACTED] (b) (6) >

**Date:** Thursday, February 20, 2020 at 12:17 PM

**To:** "Tabak, Lawrence (NIH/OD) [E]" [REDACTED] (b) (6)

**Cc:** "Steele, Danielle (HHS/IOS)" [REDACTED] (b) (6)

**Subject:** RE: SARS CoV-2 in humanized mice

Larry

(b) (5)

**Brett P. Giroir, MD**

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: [REDACTED] (b) (6)

---

**From:** Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6)

**Sent:** Wednesday, February 19, 2020 11:04 PM

**To:** Giroir, Brett (HHS/OASH) [REDACTED] (b) (6)

**Cc:** Steele, Danielle (HHS/IOS) [REDACTED] (b) (6)

**Subject:** FW: SARS CoV-2 in humanized mice

Brett,

(b) (5)

Thanks for your consideration,

Larry

---

**From:** "Hasenkrug, Kim (NIH/NIAID) [E]" [REDACTED] (b) (6)

**Date:** Wednesday, February 19, 2020 at 5:50 PM

To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)

Subject: SARS CoV-2 in humanized mice

Hi Dr. Tabak,

(b) (5)

(b) (5)

Best regards,

Kim

Kim J Hasenkrug, Ph.D.  
Senior Investigator  
Chief, Retroviral Immunology Section  
Laboratory of Persistent Viral Diseases  
Rocky Mountain Laboratories  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
903 S. 4th Street  
Hamilton, MT 59840

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Mon, 2 Mar 2020 00:48:25 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]; Giroir, Brett (HHS/OASH)  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: COVID and Chloroquine

Thanks, Cristina

---

**From:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >  
**Sent:** Sunday, March 1, 2020 7:06 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) Giroir, Brett (HHS/OASH)  
(b) (6)  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Subject:** RE: COVID and Chloroquine

Hi,

Sorry for the late response, I just flew back from (b) (6).

NIAD doesn't have ongoing trials with chloroquine and I heard that such trials are being conducted in China.

We are planning to evaluate chloroquine in animal models ASAP. If any therapeutic with a good clinical safety profile ( like chloroquine) appears to be effective in vivo against COVID-19, we are planning to quickly add to them to the Remdesivir therapeutic trial as another arm.

Let me know if you have other questions.

Kind regards,

Cristina

Cristina Cassetti, Ph.D.  
Deputy Director  
Division of Microbiology and Infectious Diseases  
National Institute of Allergy and Infectious Diseases, NIH  
[5601 Fishers Lane](#), Room 7G51  
[Rockville, MD 20852](#)

Tel: (b) (6)  
(b) (6)

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Sent:** Saturday, February 29, 2020 8:20 PM

**To:** Giroir, Brett (HHS/OASH) (b) (6)>  
**Cc:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Subject:** RE: COVID and Chloroquine  
**Importance:** High

Brett:

Thanks for the note. I will run this by the people in our Program and get back to you.

Best,

Tony

Cristina:

Are we or anyone else doing anything with clinical trials and chloroquine for COVID-19? Please respond directly to ADM Giroir.

Thanks,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Giroir, Brett (HHS/OASH) (b) (6)>  
**Sent:** Saturday, February 29, 2020 9:31 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** COVID and Chloroquine

You know the old data and the new data. New in vitro look promising.  
Do you have good visibility on the trials being conducted? Or is NIH running any of these?

Your time is precious, so 10 word response sufficient.



**Brett P. Giroir, MD**

ADM, US Public Health Service  
Assistant Secretary for Health (ASH)  
200 Independence Avenue, SW  
Washington, DC 20201

Office Phone: [REDACTED] (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 22:35:38 +0000  
**To:** Kadlec, Robert (OS/ASPR/IO)  
**Subject:** RE: Your thoughts

My thoughts – (b) (5)

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Kadlec, Robert (OS/ASPR/IO) (b) (6) >  
**Sent:** Saturday, February 29, 2020 10:03 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Your thoughts  
**Importance:** High

Tony I don't know if you saw this but wanted to ask your thought. (b) (5)  
(b) (6) Your thoughts always appreciated  
bob

<< File: CCDC Epi Report.pptx >> << File:  
The+Epidemiological+Characteristics+of+an+Outbreak+of+2019+Novel+Coronavirus+Diseases+(  
COVID-19)+—+China,+2020.pdf >>

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 03:55:20 +0000  
**To:** Collins, Francis (NIH/OD) [E]  
**Cc:** Tabak, Lawrence (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

I would recommend Dr. Hilary Marston from my immediate office. Larry should go to the hearing with us

---

**From:** Collins, Francis (NIH/OD) [E] (b) (6)  
**Sent:** Saturday, February 29, 2020 10:48 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Tabak, Lawrence (NIH/OD) [E] (b) (6) >  
**Subject:** FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony,

Quick question – who would you suggest is the appropriate NIH representative for this ASPR-led trans-HHS effort to coordinate COVID-19 response? You and I will be testifying in front of the House Approps Subcommittee on Wednesday morning. Would it be best for Larry to represent NIH for the ASPR gathering (though he would normally attend the House hearing), or is there someone from NIAID that would be most appropriate?

Thanks, Francis

---

**From:** Kadlec, Robert (OS/ASPR/IO) (b) (6)  
**Sent:** Friday, February 28, 2020 10:23 AM  
**To:** Trueman, Laura (HHS/IEA) (b) (6) >; Rowell, Scott (OS/ASA) (b) (6) >; Bird, Catherine (OS/OGC) (b) (6) >; Moughalian, Jen (HHS/ASFR) (b) (6) >; Arbes, Sarah (HHS/ASL) < (b) (6) >; Murphy, Ryan (OS/ASPA) (b) (6) >; Destro, Brenda (HHS/ASPE) (b) (6) >; Giroir, Brett (HHS/OASH) (b) (6) >; Severino, Roger (HHS/OCR) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) (b) (6); Charrow, Robert (HHS/OGC) < (b) (6); Grimm, Christi A (OIG/IO) (b) (6) >; Griswold, Nancy (HHS/OMHA HQ) (b) (6) >; Op Divs (b) (6) >; Johnson, Lynn (ACF) (b) (6) >; Robertson, Lance (ACL) (b) (6) >; Khanna, Gopal (AHRQ/IOD) (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Verma, Seema (CMS/OA) (b) (6) >; Saxon, Bobby (CMS/CCIIO) (b) (6) >; Hinton, Denise (FDA/OC) (b) (6) >



(b) (6); Engels, Thomas (HRSA) (b) (6); Weahkee, Michael (IHS/HQ) < (b) (6)>; McCollum, Jeffrey T (IHS/HQ) (b) (6); Frazier, Francis (IHS/HQ) < (b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); McCance-Katz, Elinore (SAMHSA/OAS) < (b) (6)>; Krohmer, Jon (dot.gov) (b) (6)  
**Cc:** Ford-Barnes, Arwenchia (OS/ASPR/IO) (b) (6); Waters, Cicely (OS/ASPR/OEA) < (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6)  
**Subject:** HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to [ASPR.HCSRTF@hhs.gov](mailto:ASPR.HCSRTF@hhs.gov) no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)



- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec  
ASPR

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 03:26:56 +0000  
**To:** Collins, Francis (NIH/OD) [E]  
**Subject:** RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Francis:

You are correct about the Israeli vaccine. I cannot imagine that they would have a safe and effective vaccine deployable in 90 days.

Tony

---

**From:** Collins, Francis (NIH/OD) [E] (b) (6) >  
**Sent:** Friday, February 28, 2020 12:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Tabak, Lawrence (NIH/OD) [E] (b) (6)  
**Subject:** FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony and Larry,

See below for a new Health Care Resilience Task Force being convened by ASPR.

The initial meeting overlaps with our House approps hearing.

Tony, who shall we send to this one?

FC

P.S. to Tony – I'm getting a lot of buzz about the Israeli claim to have fast track vaccine: <https://israelb.org/2020/02/israel-to-have-coronavirus-vaccine-within-3-weeks/> It looks to me that they are conflating having something ready to put into volunteers for a phase 1 trial, and having full scale production ready to go for the global needs. That still seems like it's a year away. Am I right?

---

**From:** Kadlec, Robert (OS/ASPR/IO) (b) (6)  
**Sent:** Friday, February 28, 2020 10:23 AM  
**To:** Trueman, Laura (HHS/IEA) (b) (6) >; Rowell, Scott (OS/ASA) (b) (6); Bird, Catherine (OS/OGC) (b) (6) >; Moughalian, Jen (HHS/ASFR) (b) (6); Arbes, Sarah (HHS/ASL) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>; Destro, Brenda (HHS/ASPE) (b) (6); Giroir, Brett (HHS/OASH) <(b) (6)>; Severino, Roger (HHS/OCR) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA)

< (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) < (b) (6) >;  
Charrow, Robert (HHS/OGC) < (b) (6) >; Grimm, Christi A (OIG/IO)  
< (b) (6) >; Griswold, Nancy (HHS/OMHA HQ) (b) (6) >;  
Op Divs (b) (6) >; Johnson, Lynn (ACF) < (b) (6) >;  
Robertson, Lance (ACL) (b) (6) >; Khanna, Gopal (AHRQ/IOD)  
(b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Verma, Seema  
(CMS/OA) < (b) (6) >; Saxon, Bobby (CMS/CCIO)  
< (b) (6) > Hinton, Denise (FDA/OC)  
(b) (6) >; Engels, Thomas (HRSA) < (b) (6) >; Weahkee, Michael  
(IHS/HQ) (b) (6) >; McCollum, Jeffrey T (IHS/HQ)  
(b) (6) >; Frazier, Francis (IHS/HQ) < (b) (6) > Collins,  
Francis (NIH/OD) [E] < (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]  
(b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; McCance-  
Katz, Elinore (SAMHSA/OAS) (b) (6) >; Krohmer, Jon (dot.gov)  
(b) (6) >  
**Cc:** Ford-Barnes, Arwenchia (OS/ASPR/IO) (b) (6) >; Waters, Cicely  
(OS/ASPR/OEA) (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6) >  
**Subject:** HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to [ASPR.HCSRTF@hhs.gov](mailto:ASPR.HCSRTF@hhs.gov) no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)
- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec  
ASPR



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 27 Feb 2020 15:45:23 +0000  
**To:** Zebley, Kyle (HHS/OS/OGA)  
**Cc:** Kerr, Lawrence (HHS/OS/OGA)  
**Subject:** RE: Current TF Agenda Draft/Request for AMA High-level Talkers  
**Attachments:** Task Force VP Briefing 2-13-20 - with Fauci TP.docx

Kyle:

Here is a talking point for the messaging section.

Best,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Zebley, Kyle (HHS/OS/OGA) (b) (6)  
**Sent:** Thursday, February 27, 2020 9:11 AM  
**To:** Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>; Trueman, Laura (HHS/IEA) (b) (6); Johnston, Darcie (HHS/IEA) (b) (6); Arbes, Sarah (HHS/ASL) <(b) (6)>; Morse, Sara (HHS/ASL) (b) (6); Twomey, John K. (HHS/ASL) (b) (6); Pence, Laura (HHS/ASL) (b) (6)>  
**Cc:** Mango, Paul (HHS/IOS) (b) (6); Bird, Catherine (OS/OGC) <(b) (6)>; Grigsby, Garrett (HHS/OS/OGA) (b) (6); Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)  
**Subject:** Current TF Agenda Draft/Request for AMA High-level Talkers  
**Importance:** High

Good morning,

Attached, please find a current draft of an agenda for a TF Briefing for VPOTUS this afternoon. Note that this is a draft and is not final. However, in order to prepare the Secretary, can ASPA, IEA, and ASL please help with 2-3 high-level talkers each the Secretary could highlight under the External Activity/Messaging section of the agenda? Could you please send to me and Dr. Larry Kerr by **11 AM this morning?** Apologies for the quick turnaround.

Dr. Redfield, Dr. Fauci, and Dr. Kadlec, please note your presence on the agenda and please be prepared to speak to the topics assigned.

Let me know if you have any questions. Thanks for your help.

Kyle Zebley  
Chief of Staff  
Office of Global Affairs (OGA)  
Office of the Secretary  
U.S. Department of Health and Human Services  
Direct: (b) (6) / Mobile: (b) (6)

*Confidential and pre-decisional communication*

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 20:08:22 +0000  
**To:** Messonnier, Nancy (CDC/DDID/NCIRD/OD)  
**Subject:** RE: mitigation in communities  
**Attachments:** COVID-19 Targeted Layered Mitigation Strategy\_Interim.022820.pdf

I assume that you are OK with the document that Garrett just sent around. See attached.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6) >  
**Sent:** Sunday, March 1, 2020 2:59 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** FW: mitigation in communities

---

**From:** Messonnier, Nancy (CDC/DDID/NCIRD/OD)  
**Sent:** Sunday, March 1, 2020 2:59 PM  
**To:** Redfield, Robert R. (CDC/OD) (b) (6) >  
**Cc:** Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <(b) (6)> Schuchat, Anne MD (CDC/OD) (b) (6) >  
**Subject:** mitigation in communities

Here are the basic high level principles of a mitigation strategy. (b) (5)

(b) (5)



(b) (5)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:02:24 +0000  
**To:** Grigsby, Garrett (HHS/OS/OGA)  
**Subject:** RE: [REDACTED] (b) (5)

It is a tough decision, [REDACTED] (b) (5).

---

**From:** Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6) >  
**Sent:** Thursday, February 27, 2020 5:27 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Kadlec, Robert (OS/ASPR/IO) [REDACTED] (b) (6); Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >  
**Cc:** Harrison, Brian (HHS/IOS) [REDACTED] (b) (6); Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6) >  
**Subject:** FW: [REDACTED] (b) (5)  
**Importance:** High

Gentlemen,

Any problem with this – see Marty’s below. Need to know asap as I’d like to forward to NSC immediately. Many thanks!

---

**From:** Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6)  
**Sent:** Thursday, February 27, 2020 5:08 PM  
**To:** Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6) >  
**Cc:** Walker, Allison Taylor. (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6); Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6); Elvander, Erika (OS/OGA) [REDACTED] (b) (6) >; Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6) >; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [REDACTED] (b) (6)  
**Subject:** [REDACTED] (b) (5)

Hi Garrett,

CDC intends [REDACTED] (b) (5)  
[REDACTED] (b) (5)

Thanks,  
Marty

[REDACTED] (b) (5)

(b) (5)

**From:** (b) (6)  
**Sent:** Mon, 2 Mar 2020 08:32:20 -0500  
**To:** Tabak, Lawrence (NIH/OD) [E]  
**Cc:** Collins, Francis (NIH/OD) [E]; Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Re: TIME SENSITIVE

Larry:

Let Hilary do this. I am on a conference call.

Thanks,

Tony

On Mar 2, 2020, at 8:27 AM, Tabak, Lawrence (NIH/OD) [E]

(b) (6) >wrote:

Tony –

Could one of your folks give me a quick read out on this please? (should I reach out to Hilary Marston?). This is the paper that DOE alluded to in the initial conference call we had with OSTP. I will respond informed by your staff's guidance.

Larry

---

**From:** "Mango, Paul (HHS/IOS)" (b) (6) >  
**Date:** Monday, March 2, 2020 at 8:19 AM  
**To:** Stephen Hahn <(b) (6)>, "Lenihan, Keagan (FDA/OC)" (b) (6) >, Anthony Fauci <(b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" (b) (6) >, "Redfield, Robert R. (CDC/OD)" (b) (6) >, "McGowan, Robert (Kyle) (CDC/OD/OCS)" (b) (6) >, "Berger, Sherri (CDC/OCOO/OD)" (b) (6) >  
**Cc:** "Harrison, Brian (HHS/IOS)" (b) (6) >  
**Subject:** TIME SENSITIVE

Dr Hahn and the FDA team in particular, but with input from relevant SMEs at CDC and NIH, please give the brief attached document and quick read on comment on the usefulness of us setting up a session with the folks at DOE today to discuss further. Many thanks

Sent from my iPhone

Begin forwarded message:

**From:** "Harrison, Brian (HHS/IOS)" <(b) (6)>  
**Date:** March 1, 2020 at 6:15:54 AM EST  
**To:** (b) (6) (OS/IOS)" <(b) (6)>  
**Cc:** "Stecker, Judy (OS/IOS)" (b) (6), "Mango, Paul (HHS/IOS)" (b) (6)>  
**Subject:** FW:

With attachment. I've asked CDC, FDA, NIH, and ASPR to review.

---

**From:** Brouillette, Dan (b) (6)  
**Sent:** Friday, February 28, 2020 9:58 PM  
**To:** Harrison, Brian (HHS/IOS) (b) (6)  
**Subject:**

Brian:

As we discussed earlier this evening, here's a preliminary finding from scientists at Oak Ridge National Laboratory using the Summit supercomputer system. We stand ready to assist in any manner helpful to you and Secretary Azar. Very best,

Dan

Sent with BlackBerry Work  
([www.blackberry.com](http://www.blackberry.com))

<coronavirus.pdf>



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 1 Mar 2020 01:17:02 +0000  
**To:** Harper, Jill (NIH/NIAID) [E]  
**Subject:** RE: Approps TA: DOE Reimbursement for Coronavirus Super Computing

(b) (5)

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Harper, Jill (NIH/NIAID) [E] (b) (6)  
**Sent:** Saturday, February 29, 2020 9:43 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Haskins, Melinda (NIH/NIAID) [E] (b) (6)  
**Subject:** Re: Approps TA: DOE Reimbursement for Coronavirus Super Computing

Tony,

(b) (5)

Thanks,  
Jill

---

**From:** "Harper, Jill (NIH/NIAID) [E]" (b) (6)  
**Date:** Friday, February 28, 2020 at 5:33:38 PM

**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>  
**Subject:** Fwd: Approps TA: DOE Reimbursement for Coronavirus Super Computing

Tony, I will call you about this in a minute

---

**From:** "Haskins, Melinda (NIH/NIAID) [E]" (b) (6)  
**Date:** Friday, February 28, 2020 at 5:24:43 PM  
**To:** "Mitchell, Michelle (NIH/OD) [E]" (b) (6)>  
**Cc:** "NIAID OCGR Leg" <[NIAIDOCGRLeg@mail.nih.gov](mailto:NIAIDOCGRLeg@mail.nih.gov)>, "LaMontagne, Karen (NIH/OD) [E]" (b) (6), "Harper, Jill (NIH/NIAID) [E]" (b) (6), "Johnson, Martin S. (NIH/NIAID) [E]" (b) (6), "Billet, Courtney (NIH/NIAID) [E]" (b) (6), "Shapiro, Neil (NIH/OD) [E]" (b) (6)  
**Subject:** Re: Approps TA: (b) (5)

(b) (5)

Sent from my iPhone

On Feb 28, 2020, at 5:17 PM, Mitchell, Michelle (NIH/OD) [E] (b) (6)> wrote:

Hi Melinda,

Would you let me know what you all think of this language?

Thanks.

MM

---

**From:** Friedel, Laura (Appropriations) (b) (6)>  
**Sent:** Friday, February 28, 2020 5:13 PM  
**To:** Haskins, Melinda (NIH/NIAID) [E] (b) (6)>; Mitchell, Michelle (NIH/OD) [E] (b) (6)  
**Subject:** RE: DOE Reimbursement for Coronavirus Super Computing

Any progress on this Michelle? Here is language that I'm thinking of.

For an additional amount for "National Institute of Allergy and Infectious Diseases", to prevent, prepare for, and respond to SARS-CoV-2, a virus strain mutating therefrom ("coronavirus"), or other emerging or reemerging infectious disease threats, domestically or internationally, \$xxx,000,000, to remain available

until September 30, 2024: *[Provided, That up to \$99,500,000 of such amounts may be transferred to the Department of Energy to provide support and access to scientific user facilities, including equipment, enabling technologies, and personnel associated with the operations of those scientific user facilities:]*

Laura Friedel  
Majority Clerk  
Committee on Appropriations  
Subcommittee on Labor, HHS and Education  
136 Dirksen Senate Office Building  
Washington, DC 20510

(b) (6)

---

**From:** Friedel, Laura (Appropriations)  
**Sent:** Friday, February 28, 2020 3:13 PM  
**To:** Haskins, Melinda (NIH/NIAID) [E] (b) (6); Michelle Mitchell  
(b) (6)  
**Subject:** DOE Reimbursement for Coronavirus Super Computing

Hi,

Dept. of Energy is looking for \$99.5 million. They are concerned that NIH will use their super computers for coronavirus (which NIH doesn't pay for) and displace paying customers. What is the expectation that NIH will need to use DOE super computers? We would include additional funds (please make sure TF knows I would not take his funds and give to DOE), but this seems extremely high to me and I was trying to understand the need from your perspective for these super computers. Happy to jump on the phone if that is easier, but need this as fast as you can get it to me please – within the next hour or so. Language is below. Thank you!

Sec. \_\_\_\_ (a) Funds appropriated in this title may be made available to restore amounts, either directly or through reimbursement, for obligations incurred by agencies of the Department of Health and Human Services for the purposes provided herein prior to the date of enactment of this Act. This subsection shall not apply to obligations incurred by the Infectious Diseases Rapid Response Reserve Fund.

(b) Funds appropriated in this title [may/shall] be used when [awarding/to award] grants and cooperative agreements in fiscal year 2020 to reimburse State or local costs incurred for the purposes provided herein after January 20, 2020, and prior to the issuance of such awards.

[(c) Funds appropriated in this title shall be transferred to other federal agencies for costs related to medical screening for coronavirus including any costs



incurred through a grant, cooperative agreement, other transaction, or contract and, once transferred, may be used to reimburse obligations incurred for such purposes prior to enactment of this Act.]

(d) Up to \$99,500,000 of the funds appropriated in this title may be transferred to the Department of Energy to provide support and access to scientific user facilities, including equipment, enabling technologies, and personnel associated with the operations of those scientific user facilities.

(e) If any funds have been reprogrammed or transferred from an appropriation, as described in the notification submitted by the Secretary to the Committees on Appropriations of the House of Representatives and the Senate on February 2, 2020, prior to the date of enactment of this Act, such amounts shall be reprogrammed or transferred back to that appropriation within 45 days of the date of enactment of this Act.

Laura Friedel  
Majority Clerk  
Committee on Appropriations  
Subcommittee on Labor, HHS and Education  
136 Dirksen Senate Office Building  
Washington, DC 20510

(b) (6)